Clinical trial results:
A Phase I/III Randomized, Double-blind Study to Evaluate the Safety, Efficacy, and Neutralizing Activity of AZD5156/AZD3152 for Pre-exposure Prophylaxis of COVID-19 in Participants with Conditions Causing Immune Impairment (Main Cohort/Sentinel Safety Cohort)

A Phase II Open Label Sub-study to Evaluate the Safety, PK, and Neutralizing Activity of AZD3152 for Pre-exposure Prophylaxis of COVID-19 (Sub-study)

Summary

EudraCT number	2022-002378-95
Trial protocol	BE DK DE PL ES FR SE
Global end of trial date	18 February 2025

Results information

Result version number	v1
This version publication date	24 August 2025
First version publication date	24 August 2025

Trial information

Trial identification

Sponsor protocol code	D7000C00001

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	-
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	AstraZeneca
Sponsor organisation address	151, 85, Södertälje, Sweden,
Public contact	AstraZeneca, Global Clinical Lead, 001 877-240-9479, information.center@astrazeneca.com
Scientific contact	AstraZeneca, Global Clinical Lead, 001 877-240-9479, information.center@astrazeneca.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	18 February 2025
Is this the analysis of the primary completion data?	No

Global end of trial reached?	Yes
Global end of trial date	18 February 2025
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

Main Cohort:
- To evaluate the safety of AZD3152 and EVUSHELD and/or placebo.
- To compare the efficacy of AZD3152 to EVUSHELD and/or placebo in the prevention of symptomatic COVID-19 caused by any SARS-CoV-2 variant.
- To compare the efficacy of AZD3152 to EVUSHELD and/or placebo in the prevention of symptomatic COVID 19 attributable to matched variants (variants that do not contain the F456L mutation).

Sentinel:
- To evaluate the safety of AZD5156

Sub-study:
- To evaluate the safety of AZD3152 and EVUSHELD
- To compare the predicted SARS-CoV-2 nAb responses to XBB.1.5 variant (or other circulating VOC) following AZD3152 administration vs predicted SARS-CoV-2 nAb responses to Alpha variant following EVUSHELD administration

Protection of trial subjects:

The study was performed in compliance with International Council for Harmonisation (ICH) Good Clinical Practice, including the archiving of essential documents.

Background therapy: -

Evidence for comparator:

Prior to CSP v7.0, the comparator for the Main Cohort was EVUSHELD as the immunobridging portion of the study was incorporated into the Parent study. At the request of regulatory authorities, a sub-study specifically for immunobridging was undertaken (which was conducted in the US only). As a result, the Parent study was an efficacy and safety study, and the comparator was changed to placebo.

Actual start date of recruitment	31 March 2023
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Australia: 186
Country: Number of subjects enrolled	Belgium: 27
Country: Number of subjects enrolled	Denmark: 73
Country: Number of subjects enrolled	France: 81
Country: Number of subjects enrolled	Germany: 148
Country: Number of subjects enrolled	Israel: 11

Country: Number of subjects enrolled	Malaysia: 41
Country: Number of subjects enrolled	Poland: 18
Country: Number of subjects enrolled	Singapore: 5
Country: Number of subjects enrolled	Korea, Republic of: 6
Country: Number of subjects enrolled	Spain: 181
Country: Number of subjects enrolled	Taiwan: 4
Country: Number of subjects enrolled	Thailand: 49
Country: Number of subjects enrolled	United Arab Emirates: 53
Country: Number of subjects enrolled	United Kingdom: 194
Country: Number of subjects enrolled	United States: 2727
Country: Number of subjects enrolled	Viet Nam: 42
Country: Number of subjects enrolled	Canada: 13
Worldwide total number of subjects	3859
EEA total number of subjects	528

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	15
Adults (18-64 years)	2543
From 65 to 84 years	1272
85 years and over	29

Subject disposition

Recruitment

Recruitment details:

In Main Cohort, 3338 participants 12 years of age or older were randomized 1:1 to receive AZD3152 or comparator.

In Sentinel Cohort, 57 participants were randomized 5:2 to receive AZD5156 (41 participants) or Placebo (16 participants).

In Sub-study, 476 participants, 18 years of age or older, were randomized 2:1 to receive AZD3152 or AZD7442.

Pre-assignment

Screening details:

Overall 3713 participants were screened in the Main Study; 87 screened for the Sentinel Cohort; 576 participants were screened in the Sub-study.

Period 1

Period 1 title	Overall study (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Investigator, Monitor, Carer, Data analyst, Assessor, Subject

Arms

Are arms mutually exclusive?	Yes
Arm title	AZD3152 - Main Cohort

Arm description: -

Arm type	Experimental
Investigational medicinal product name	AZD3152
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Intramuscular use

Dosage and administration details:

1 dose of AZD3152 300 mg IM on 2 occasions with a 6-month interval.

Arm title	AZD7442 - Main Cohort

Arm description: -

Arm type	Active comparator
Investigational medicinal product name	AZD7442
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Intramuscular use

Dosage and administration details:

1 dose of AZD7442, followed by placebo at 6 months.

Arm title	Placebo - Main Cohort

Arm description: -

Arm type	Placebo

Investigational medicinal product name	Placebo (0.9% sodium chloride)
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Intramuscular use

Dosage and administration details:

1 dose of placebo on 2 occasions with a 6-month interval.

Arm title	AZD5156 - Sentinel Cohort

Arm description: -

Arm type	Experimental
Investigational medicinal product name	AZD5156
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Intramuscular use

Dosage and administration details:

1 dose 600 mg AZD5156 at Day 1

Arm title	Placebo - Sentinel Cohort

Arm description: -

Arm type	Placebo
Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Intramuscular use

Dosage and administration details:

1 dose placebo at Day 1

Arm title	AZD3152 1200 mg - Sub Study

Arm description: -

Arm type	Experimental
Investigational medicinal product name	AZD3152
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Intramuscular use

Dosage and administration details:

1 dose of AZD3152 1200 mg at Day 1

Arm title	EVUSHELD 300 mg - Sub Study

Arm description: -

Arm type	Active comparator
Investigational medicinal product name	EVUSHELD
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Intramuscular use

Dosage and administration details:

1 dose of EVUSHELD 300 mg at Day 1; immunocompromised participants who received EVUSHELD at Day 1 were offered the option of receiving AZD3152 1200 mg after Day 29 assessment.

Number of subjects in period 1	AZD3152 - Main Cohort	AZD7442 - Main Cohort	Placebo - Main Cohort
Started	1671	1102	561
Completed	1469	962	513
Not completed	202	140	48
Adverse event, serious fatal	40	24	6
Physician decision	18	15	3
Consent withdrawn by subject	90	71	23
Adverse event, non-fatal	3	1	-
Lost to follow-up	47	29	14
Missing reason	4	-	2

Number of subjects in period 1	AZD5156 - Sentinel Cohort	Placebo - Sentinel Cohort	AZD3152 1200 mg - Sub Study
Started	41	16	310
Completed	37	13	277
Not completed	4	3	33
Adverse event, serious fatal	1	-	2
Physician decision	-	-	1
Consent withdrawn by subject	-	1	14
Adverse event, non-fatal	-	-	-
Lost to follow-up	3	2	15
Missing reason	-	-	1

Number of subjects in period 1	EVUSHELD 300 mg - Sub Study
Started	158
Completed	142
Not completed	16
Adverse event, serious fatal	-
Physician decision	3
Consent withdrawn by subject	3
Adverse event, non-fatal	1
Lost to follow-up	7
Missing reason	2

Baseline characteristics

Reporting groups	
Reporting group title	AZD3152 - Main Cohort
Reporting group description: -	
Reporting group title	AZD7442 - Main Cohort
Reporting group description: -	
Reporting group title	Placebo - Main Cohort
Reporting group description: -	
Reporting group title	AZD5156 - Sentinel Cohort
Reporting group description: -	
Reporting group title	Placebo - Sentinel Cohort
Reporting group description: -	
Reporting group title	AZD3152 1200 mg - Sub Study
Reporting group description: -	
Reporting group title	EVUSHELD 300 mg - Sub Study
Reporting group description: -	

Reporting group values	AZD3152 - Main Cohort	AZD7442 - Main Cohort	Placebo - Main Cohort
Number of subjects	1671	1102	561
Age Categorical Units: participants			
In utero	0	0	0
Preterm newborn infants (gestational age < 37 wks)	0	0	0
Newborns (0-27 days)	0	0	0
Infants and toddlers (28 days-23 months)	0	0	0
Children (2-11 years)	0	0	0
Adolescents (12-17 years)	8	7	0
Adults (18-64 years)	1057	678	375
From 65-84 years	597	403	181
85 years and over	9	14	5
Age Continuous Units: years			
arithmetic mean	58.1	58.6	57.7
standard deviation	± 13.9	± 13.7	± 13.2
Gender Categorical Units: participants			
Female	954	610	329
Male	717	492	232
Ethnicity Units: Subjects			
Hispanic or Latino	356	235	125
Not Hispanic or Latino	1240	841	386
Not reported	75	26	50
Race Units: Subjects			
Black or African American	202	122	78

Native Hawaiian or Other Pacific Islander	5	2	0
American Indian or Alaska Native	1	2	2
White	1241	814	416
Other	133	123	22
Multiple	42	31	2
Not reported	38	8	29
Missing	9	0	12
SARS-CoV-2 vaccination status within 6 months prior to randomization			
Units: Subjects			
Yes SARS-CoV-2 vaccination	199	147	50
No SARS-CoV-2 vaccination	1472	955	511
Prior SARS-CoV-2 infection within 6 months prior to randomization			
Units: Subjects			
Yes prior SARS-CoV-2 infection	66	58	7
No prior SARS-CoV-2 infection	1605	1044	554
EVUSHELD use within 12 months prior to randomization			
Units: Subjects			
Yes EVUSHELD use	191	148	39
No EVUSHELD use	1480	954	522
Missing	0	0	0

Reporting group values	AZD5156 - Sentinel Cohort	Placebo - Sentinel Cohort	AZD3152 1200 mg - Sub Study
Number of subjects	41	16	310
Age Categorical			
Units: participants			
In utero	0	0	0
Preterm newborn infants (gestational age < 37 wks)	0	0	0
Newborns (0-27 days)	0	0	0
Infants and toddlers (28 days-23 months)	0	0	0
Children (2-11 years)	0	0	0
Adolescents (12-17 years)	0	0	0
Adults (18-64 years)	41	16	250
From 65-84 years	0	0	60
85 years and over	0	0	0
Age Continuous			
Units: years			
arithmetic mean	35.2	32.3	48.9
standard deviation	± 11.2	± 9.5	± 15.8
Gender Categorical			
Units: participants			
Female	23	11	169
Male	18	5	141
Ethnicity			
Units: Subjects			
Hispanic or Latino	2	0	86
Not Hispanic or Latino	37	14	222
Not reported	2	2	2

Race Units: Subjects			
Black or African American	11	4	66
Native Hawaiian or Other Pacific Islander	0	0	2
American Indian or Alaska Native	0	0	0
White	27	9	233
Other	3	3	6
Multiple	0	0	2
Not reported	0	0	1
Missing	0	0	0
SARS-CoV-2 vaccination status within 6 months prior to randomization Units: Subjects			
Yes SARS-CoV-2 vaccination	3	2	13
No SARS-CoV-2 vaccination	38	14	297
Prior SARS-CoV-2 infection within 6 months prior to randomization Units: Subjects			
Yes prior SARS-CoV-2 infection	1	0	2
No prior SARS-CoV-2 infection	40	16	308
EVUSHELD use within 12 months prior to randomization Units: Subjects			
Yes EVUSHELD use	0	0	0
No EVUSHELD use	41	16	0
Missing	0	0	310

Reporting group values	EVUSHELD 300 mg - Sub Study	Total	
Number of subjects	158	3859	
Age Categorical Units: participants			
In utero	0	0	
Preterm newborn infants (gestational age < 37 wks)	0	0	
Newborns (0-27 days)	0	0	
Infants and toddlers (28 days-23 months)	0	0	
Children (2-11 years)	0	0	
Adolescents (12-17 years)	0	15	
Adults (18-64 years)	126	2543	
From 65-84 years	31	1272	
85 years and over	1	29	
Age Continuous Units: years			
arithmetic mean	48.6		
standard deviation	± 16.9	-	
Gender Categorical Units: participants			
Female	94	2190	
Male	64	1669	

Ethnicity Units: Subjects			
Hispanic or Latino	40	844	
Not Hispanic or Latino	116	2856	
Not reported	2	159	
Race Units: Subjects			
Black or African American	33	516	
Native Hawaiian or Other Pacific Islander	0	9	
American Indian or Alaska Native	1	6	
White	118	2858	
Other	5	295	
Multiple	1	78	
Not reported	0	76	
Missing	0	21	
SARS-CoV-2 vaccination status within 6 months prior to randomization Units: Subjects			
Yes SARS-CoV-2 vaccination	5	419	
No SARS-CoV-2 vaccination	153	3440	
Prior SARS-CoV-2 infection within 6 months prior to randomization Units: Subjects			
Yes prior SARS-CoV-2 infection	1	135	
No prior SARS-CoV-2 infection	157	3724	
EVUSHELD use within 12 months prior to randomization Units: Subjects			
Yes EVUSHELD use	0	378	
No EVUSHELD use	0	3013	
Missing	158	468	

End points

End points reporting groups

Reporting group title	AZD3152 - Main Cohort
Reporting group description: -	
Reporting group title	AZD7442 - Main Cohort
Reporting group description: -	
Reporting group title	Placebo - Main Cohort
Reporting group description: -	
Reporting group title	AZD5156 - Sentinel Cohort
Reporting group description: -	
Reporting group title	Placebo - Sentinel Cohort
Reporting group description: -	
Reporting group title	AZD3152 1200 mg - Sub Study
Reporting group description: -	
Reporting group title	EVUSHELD 300 mg - Sub Study
Reporting group description: -	

Primary: (Main Cohort) Occurrence of AEs collected through approximately 90 days after each IMP administration; SAEs, MAAEs, and AESIs collected throughout the study

End point title	(Main Cohort) Occurrence of AEs collected through approximately 90 days after each IMP administration; SAEs, MAAEs, and AESIs collected throughout the study[1][2]

End point description:

End point type	Primary

End point timeframe:

through 90 days post IMP administration (AEs); throughout the study (SAEs, MAAEs, and AESIs)

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: Safety data was planned to be summarized in a descriptive way without hypothesis testing.

[2] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Safety data was planned to be summarized in a descriptive way without hypothesis testing.

End point values	AZD3152 - Main Cohort	AZD7442 - Main Cohort	Placebo - Main Cohort	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	1671	1102	561	
Units: Participants				
AEs	846	591	273	
SAEs	315	222	90	
MAAEs	976	651	297	
AESIs	45	18	9	

Statistical analyses

No statistical analyses for this end point

Primary: (Sub-study) Occurrence of AEs collected through 29 days after IMP administration. SAEs, MAAEs, and AESIs collected throughout the study for the final analysis.

End point title	(Sub-study) Occurrence of AEs collected through 29 days after IMP administration. SAEs, MAAEs, and AESIs collected throughout the study for the final analysis.[3][4]

End point description:

End point type	Primary

End point timeframe:

through 29 days post IMP administration (AEs); throughout the study (SAEs, MAAEs, and AESIs)

Notes:

[3] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: Safety data was planned to be summarized in a descriptive way without hypothesis testing.

[4] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Safety data was planned to be summarized in a descriptive way without hypothesis testing.

End point values	AZD3152 1200 mg - Sub Study	EVUSHELD 300 mg - Sub Study		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	310	158		
Units: participants				
AE	81	33		
SAE	15	11		
MAAE	89	65		
AESI	9	1		

Statistical analyses

No statistical analyses for this end point

Primary: (Sub-study) Predicted SARS-CoV-2 nAb titers derived from serum PK and in vitro IC50 for SARS-CoV-2 variants BA.2.86 following AZD3152 administration and Alpha variant following EVUSHELD administration.

End point title	(Sub-study) Predicted SARS-CoV-2 nAb titers derived from serum PK and in vitro IC50 for SARS-CoV-2 variants BA.2.86 following AZD3152 administration and Alpha variant following EVUSHELD administration.[5]

End point description:

End point type	Primary

End point timeframe:

at Day 29

Notes:

[5] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Safety data was planned to be summarized in a descriptive way without hypothesis testing.

End point values	AZD3152 1200 mg - Sub Study	EVUSHELD 300 mg - Sub Study		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	281	141		
Units: ug/mL				
geometric mean (geometric coefficient of variation)				
AZD3152 [BA.2.86] / AZD7442 [Alpha]	36127.1 (± 0.56)	8882.5 (± 0.61)		

Statistical analyses

Statistical analysis title	Comparison for predicted nAb titers

Statistical analysis description:

The GMTR and its confidence intervals are estimated from an Analysis of Variance Model that includes the log10-transformed predicted nAb titers at Day 29 as the response variable and treatment arm as the primary explanatory variable.

Comparison groups	AZD3152 1200 mg - Sub Study v EVUSHELD 300 mg - Sub Study
Number of subjects included in analysis	422
Analysis specification	Pre-specified
Analysis type	superiority
Method	ANOVA
Parameter estimate	GMTR
Point estimate	4.07
Confidence interval	
level	95 %
sides	2-sided
lower limit	3.65
upper limit	4.53

Statistical analysis title	Comparison for predicted nAb titers

Statistical analysis description:

The geometric mean titer ratio (GMTR) and its confidence intervals are estimated from an Analysis of Variance Model that includes the log10-transformed predicted nAb titers at Day 29 as the response variable and treatment arm as the primary explanatory variable.

Comparison groups	AZD3152 1200 mg - Sub Study v EVUSHELD 300 mg - Sub Study

Number of subjects included in analysis	422
Analysis specification	Pre-specified
Analysis type	non-inferiority
Method	ANOVA
Parameter estimate	GMTR
Point estimate	4.07
Confidence interval	
level	90 %
sides	2-sided
lower limit	3.71
upper limit	4.46

Primary: (Main Cohort) Confirmed symptomatic COVID-19 case

End point title	(Main Cohort) Confirmed symptomatic COVID-19 case[6]

End point description:

End point type	Primary

End point timeframe:

at Primary Analysis

Notes:

[6] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: Safety data was planned to be summarized in a descriptive way without hypothesis testing.

End point values	AZD3152 - Main Cohort	AZD7442 - Main Cohort	Placebo - Main Cohort	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	1649	1082	549	
Units: participants	122	117	61	

Statistical analyses

Statistical analysis title	dual primary endpoint testing by Holm procedure

Statistical analysis description:

Comparator group combined AZD7442/Placebo groups. Relative risk reduction was defined as 1-relative risk of AZD3152/AZD3152 versus Comparator, where relative risk was evaluated with a Poisson regression with robust variance, which includes study intervention and the randomization stratification factors as covariates and adjusts follow-up time.

Comparison groups	AZD3152 - Main Cohort v AZD7442 - Main Cohort v Placebo - Main Cohort
Number of subjects included in analysis	3280
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.001 [7]
Method	Poisson regression
Parameter estimate	relative risk reduction, %
Point estimate	34.9

Confidence interval	
level	Other: 97.5 %
sides	2-sided
lower limit	15
upper limit	50.1

Notes:

[7] - first-ranked p-value in Holm procedure

Primary: (Main Cohort) Confirmed symptomatic COVID-19 case attributable to matched variants

End point title	(Main Cohort) Confirmed symptomatic COVID-19 case attributable to matched variants[8]

End point description:

End point type	Primary

End point timeframe:

at Primary Analysis

Notes:

[8] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Safety data was planned to be summarized in a descriptive way without hypothesis testing.

End point values	AZD3152 - Main Cohort	AZD7442 - Main Cohort	Placebo - Main Cohort	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	1649	1082	549	
Units: participants	54	55	35	

Statistical analyses

Statistical analysis title	dual primary endpoint testing by Holm procedure

Statistical analysis description:

Comparator group combined AZD7442/Placebo groups. Relative risk reduction was defined as 1-relative risk of AZD3152/AZD3152 versus Comparator, where relative risk was evaluated with a Poisson regression with robust variance, which includes study intervention and the randomization stratification factors as covariates and adjusts follow-up time.

Comparison groups	AZD3152 - Main Cohort v AZD7442 - Main Cohort v Placebo - Main Cohort
Number of subjects included in analysis	3280
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.001 [9]
Method	Poisson regression
Parameter estimate	relative risk reduction, %
Point estimate	42.9
Confidence interval	
level	95 %
sides	2-sided
lower limit	19.9
upper limit	59.3

Notes:

[9] - second-ranked p-value in Holm procedure

Primary: (Sentinel Cohort) Occurrence of AEs, SAEs, MAAEs, and AESIs collected throughout the study

End point title	(Sentinel Cohort) Occurrence of AEs, SAEs, MAAEs, and AESIs collected throughout the study[10][11]

End point description:

End point type	Primary

End point timeframe:

throughout the study

Notes:

[10] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: Safety data was planned to be summarized in a descriptive way without hypothesis testing.

[11] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Safety data was planned to be summarized in a descriptive way without hypothesis testing.

End point values	AZD5156 - Sentinel Cohort	Placebo - Sentinel Cohort		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	41	16		
Units: participants				
AEs	19	12		
SAEs	2	0		
MAAEs	9	3		
AESIs	0	0		

Statistical analyses

No statistical analyses for this end point

Secondary: (Sub-study) AZD3152 and EVUSHELD concentrations in serum, over time

End point title	(Sub-study) AZD3152 and EVUSHELD concentrations in serum, over time[12]

End point description:

End point type	Secondary

End point timeframe:

Day 29, Day 91, Day 181

Notes:

[12] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Safety data was planned to be summarized in a descriptive way without hypothesis testing.

End point values	AZD3152 1200 mg - Sub Study	EVUSHELD 300 mg - Sub Study		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	299	154		
Units: ug/mL				
geometric mean (geometric coefficient of variation)				
Day 29	133.4 (± 0.72)	21.2 (± 0.62)		
Day 91	69.6 (± 0.82)	14.6 (± 0.67)		
Day 181	30.3 (± 1.64)	6.6 (± 1.00)		

Statistical analyses

No statistical analyses for this end point

Secondary: (Sub-study) Incidence of ADA to AZD3152 and EVUSHELD

End point title	(Sub-study) Incidence of ADA to AZD3152 and EVUSHELD[13]

End point description:

AZD3152 recipients were tested for ADA to AZD3152; EVUSHELD recipients were tested for ADA to EVUSHELD.

End point type	Secondary

End point timeframe:

through Day 181

Notes:

[13] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Safety data was planned to be summarized in a descriptive way without hypothesis testing.

End point values	AZD3152 1200 mg - Sub Study	EVUSHELD 300 mg - Sub Study		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	297	151		
Units: participants				
Treatment-emergent ADA positive (ADA incidence)	2	0		

Statistical analyses

No statistical analyses for this end point

Secondary: (Sub-study) Cilgavimab and tixagevimab concentrations in serum, over time

End point title	(Sub-study) Cilgavimab and tixagevimab concentrations in serum, over time[14]

End point description:

End point type	Secondary

End point timeframe:

Day 29, Day 91, Day 181

Notes:

[14] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Safety data was planned to be summarized in a descriptive way without hypothesis testing.

End point values	EVUSHELD 300 mg - Sub Study			
Subject group type	Reporting group			
Number of subjects analysed	154			
Units: ug/mL				
geometric mean (geometric coefficient of variation)				
Cilgavimab: Day 29	8.9 (± 0.65)			
Cilgavimab: Day 91	7.0 (± 0.68)			
Cilgavimab: Day 181	3.2 (± 0.84)			
Tixagevimab: Day 29	9.4 (± 0.64)			
Tixagevimab: Day 91	7.6 (± 0.66)			
Tixagevimab: Day 181	3.5 (± 0.89)			

Statistical analyses

No statistical analyses for this end point

Secondary: (Sub-study) ADA titers

End point title	(Sub-study) ADA titers[15]

End point description:

ADA titers were only available for ADA positive samples.

End point type	Secondary

End point timeframe:

Day 1, Day 29, Day 91, Day 181

Notes:

[15] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Safety data was planned to be summarized in a descriptive way without hypothesis testing.

End point values	AZD3152 1200 mg - Sub Study	EVUSHELD 300 mg - Sub Study		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	297	151		
Units: ADA titers				
median (full range (min-max))				
Day 1	200 (100 to 800)	80 (40 to 640)		
Day 29	0 (0 to 0)	80 (40 to 160)		
Day 91	100 (100 to 100)	80 (40 to 160)		

Day 181	100 (100 to 400)	80 (80 to 80)		

Statistical analyses

No statistical analyses for this end point

Secondary: (Main Cohort) Symptomatic COVID19 case (negative RTPCR at baseline to positive at any time up 12 months with all observed events at final readout) caused by any SARSCoV2 matched variant

End point title	(Main Cohort) Symptomatic COVID19 case (negative RTPCR at baseline to positive at any time up 12 months with all observed events at final readout) caused by any SARSCoV2 matched variant[16]

End point description:

first secondary endpoint to be tested in hierarchical testing after dual-primary endpoint efficacy was demonstrated in hierarchical testing

End point type	Secondary

End point timeframe:

through Day 361

Notes:

[16] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Safety data was planned to be summarized in a descriptive way without hypothesis testing.

End point values	AZD3152 - Main Cohort	AZD7442 - Main Cohort	Placebo - Main Cohort	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	1649	1082	549	
Units: participants	59	56	37	

Statistical analyses

Statistical analysis title	Hypothesis testing

Statistical analysis description:

Comparator group combined AZD7442/Placebo groups. Relative risk reduction was defined as 1-relative risk of AZD3152/AZD3152 versus Comparator, where relative risk was evaluated with a Poisson regression with robust variance, which includes study intervention and the randomization stratification factors as covariates and adjusts follow-up time.

Comparison groups	AZD3152 - Main Cohort v AZD7442 - Main Cohort v Placebo - Main Cohort
Number of subjects included in analysis	3280
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.003
Method	Poisson regression
Parameter estimate	relative risk reduction, %
Point estimate	39.8

Confidence interval	
level	95 %
sides	2-sided
lower limit	16.2
upper limit	56.7

Secondary: (Main Cohort) Symptomatic COVID19 case (negative RTPCR at baseline to positive at any time up to 12 months with all observed events at final readout) caused by any SARSCoV2 variants

End point title	(Main Cohort) Symptomatic COVID19 case (negative RTPCR at baseline to positive at any time up to 12 months with all observed events at final readout) caused by any SARSCoV2 variants[17]

End point description:

second secondary endpoint to be tested in hierarchical testing after dual-primary endpoint efficacy was demonstrated in hierarchical testing

End point type	Secondary

End point timeframe:

through Day 361

Notes:

[17] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Safety data was planned to be summarized in a descriptive way without hypothesis testing.

End point values	AZD3152 - Main Cohort	AZD7442 - Main Cohort	Placebo - Main Cohort	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	1649	1082	549	
Units: participants	175	147	79	

Statistical analyses

Statistical analysis title	Hypothesis testing

Statistical analysis description:

Comparator group combined AZD7442/Placebo groups. Relative risk reduction was defined as 1-relative risk of AZD3152/AZD3152 versus Comparator, where relative risk was evaluated with a Poisson regression with robust variance, which includes study intervention and the randomization stratification factors as covariates and adjusts follow-up time.

Comparison groups	AZD3152 - Main Cohort v AZD7442 - Main Cohort v Placebo - Main Cohort
Number of subjects included in analysis	3280
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.002
Method	Poisson regression
Parameter estimate	relative risk reduction, %
Point estimate	26.9

Confidence interval	
level	95 %
sides	2-sided
lower limit	10.7
upper limit	40.2

Secondary: (Main Cohort) Severe COVID19 caused by any SARSCoV2 variant any time up to 12 months

End point title	(Main Cohort) Severe COVID19 caused by any SARSCoV2 variant any time up to 12 months[18]

End point description:

third secondary endpoint to be tested in hierarchical testing after dual-primary endpoint efficacy was demonstrated in hierarchical testing

End point type	Secondary

End point timeframe:

through Day 361

Notes:

[18] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Safety data was planned to be summarized in a descriptive way without hypothesis testing.

End point values	AZD3152 - Main Cohort	AZD7442 - Main Cohort	Placebo - Main Cohort	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	1649	1082	549	
Units: participants	3	3	3	

Statistical analyses

Statistical analysis title	Hypothesis testing

Statistical analysis description:

Relative risk reduction was defined as 1-relative risk of AZD3152/AZD3152 versus Comparator, where relative risk was evaluated with a Poisson regression
with robust variance, which includes study intervention and the randomization stratification factors as covariates and adjusts for follow-up time. Only
participants with non-missing covariates are included in the analysis. If there is 0 event at any level of a stratification factor, then the stratification factor is dropped from the model.

Comparison groups	AZD3152 - Main Cohort v AZD7442 - Main Cohort v Placebo - Main Cohort
Number of subjects included in analysis	3280
Analysis specification	Pre-specified
Analysis type	superiority[19]
P-value	= 0.308
Method	Poisson regression
Parameter estimate	relative risk reduction, %
Point estimate	51.5

Confidence interval	
level	95 %
sides	2-sided
lower limit	-95.1
upper limit	87.9

Notes:

[19] - The test result was not significant, hierarchical testing procedure stopped.

Secondary: (Main Cohort) Composite of COVID19-related hospitalization and/or COVID19-related death (WHO COVID19 Clinical Progression Scale score ≥ 4) any time up to 12 months

End point title	(Main Cohort) Composite of COVID19-related hospitalization and/or COVID19-related death (WHO COVID19 Clinical Progression Scale score ≥ 4) any time up to 12 months[20]

End point description:

End point type	Secondary

End point timeframe:

through Day 361

Notes:

[20] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Safety data was planned to be summarized in a descriptive way without hypothesis testing.

End point values	AZD3152 - Main Cohort	AZD7442 - Main Cohort	Placebo - Main Cohort	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	1649	1082	549	
Units: participants	16	10	4	

Statistical analyses

No statistical analyses for this end point

Secondary: (Main Cohort) Severe COVID19 caused by any SARSCoV2 matched variants at any time up to 12 months

End point title	(Main Cohort) Severe COVID19 caused by any SARSCoV2 matched variants at any time up to 12 months[21]

End point description:

End point type	Secondary

End point timeframe:

through Day 361

Notes:

[21] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Safety data was planned to be summarized in a descriptive way without hypothesis testing.

End point values	AZD3152 - Main Cohort	AZD7442 - Main Cohort	Placebo - Main Cohort	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	1649	1082	549	
Units: participants	0	0	0	

Statistical analyses

No statistical analyses for this end point

Secondary: (Main Cohort) COVID19-related hospitalization any time up to 12 months

End point title	(Main Cohort) COVID19-related hospitalization any time up to 12 months[22]

End point description:

End point type	Secondary

End point timeframe:

through Day 361

Notes:

[22] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Safety data was planned to be summarized in a descriptive way without hypothesis testing.

End point values	AZD3152 - Main Cohort	AZD7442 - Main Cohort	Placebo - Main Cohort	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	1649	1082	549	
Units: participants	16	10	4	

Statistical analyses

No statistical analyses for this end point

Secondary: (Main Cohort) COVID-19 related death

End point title	(Main Cohort) COVID-19 related death[23]

End point description:

End point type	Secondary

End point timeframe:

through Day 361

Notes:

[23] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Safety data was planned to be summarized in a descriptive way without hypothesis testing.

End point values	AZD3152 - Main Cohort	AZD7442 - Main Cohort	Placebo - Main Cohort	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	1649	1082	549	
Units: participants	0	1	0	

Statistical analyses

No statistical analyses for this end point

Secondary: (Main Cohort) GMT and GMFR of SARS-CoV-2 nAbs at Day 29

End point title	(Main Cohort) GMT and GMFR of SARS-CoV-2 nAbs at Day

End point description:

End point type	Secondary

End point timeframe:

at Day 29

Notes:

[24] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Safety data was planned to be summarized in a descriptive way without hypothesis testing.

End point values	AZD3152 - Main Cohort	AZD7442 - Main Cohort	Placebo - Main Cohort	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	1422	1020	484	
Units: 1/dilution; ratio				
geometric mean (confidence interval 95%)				
Alpha/B.1.1.7 GMC	6400.09 (5848.79 to 7003.36)	60287.63 (54951.89 to 66141.45)	2932.50 (2616.48 to 3286.70)	
Alpha/B.1.1.7 GMFR	2.54 (2.33 to 2.78)	23.97 (21.85 to 26.30)	1.17 (1.04 to 1.31)	
BA.2 GMC	2928.45 (2678.52 to 3201.71)	8924.49 (8141.14 to 9783.23)	1029.20 (918.57 to 1153.16)	
BA.2 GMFR	3.20 (2.92 to 3.49)	9.74 (8.89 to 10.68)	1.12 (1.00 to 1.26)	
BA.4/5 GMC	4026.99 (3683.40 to 4402.63)	2975.84 (2714.31 to 3262.57)	840.04 (749.95 to 940.95)	
BA.4/5 GMFR	5.68 (5.20 to 6.21)	4.20 (3.83 to 4.60)	1.19 (1.06 to 1.33)	
XBB.1.5 GMC	2385.68 (2143.34 to 2655.42)	151.79 (135.82 to 169.64)	196.29 (170.85 to 225.53)	
XBB.1.5 GMFR	15.69 (14.09 to 17.46)	1.00 (0.89 to 1.12)	1.29 (1.12 to 1.48)	

Statistical analyses

No statistical analyses for this end point

Secondary: (Main Cohort) AZD3152 and AZD7442 (EVUSHELD) concentrations over time

End point title	(Main Cohort) AZD3152 and AZD7442 (EVUSHELD) concentrations over time[25]

End point description:

End point type	Secondary

End point timeframe:

through Day 361

Notes:

[25] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Safety data was planned to be summarized in a descriptive way without hypothesis testing.

End point values	AZD3152 - Main Cohort	AZD7442 - Main Cohort		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	895	780		
Units: mg/L				
geometric mean (geometric coefficient of variation)				
Day 29	30.1 (± 35.9)	61.0 (± 41.5)		
Day 91	18.2 (± 49.8)	35.0 (± 56.8)		
Day 181	8.9 (± 85.9)	15.6 (± 68.5)		
Day 189	33.4 (± 73.0)	14.6 (± 72.3)		
Day 210	33.0 (± 50.8)	12.5 (± 75.7)		
Day 361	12.0 (± 67.4)	3.7 (± 80.7)		

Statistical analyses

No statistical analyses for this end point

Secondary: (Sentinel Cohort) AZD5156, AZD1061, and AZD3152 concentrations over time

End point title	(Sentinel Cohort) AZD5156, AZD1061, and AZD3152 concentrations over time[26]

End point description:

End point type	Secondary

End point timeframe:

Day 29, Day 181, Day 361

Notes:

[26] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Safety data was planned to be summarized in a descriptive way without hypothesis testing.

End point values	AZD5156 - Sentinel Cohort			
Subject group type	Reporting group			
Number of subjects analysed	20			
Units: mg/L				
geometric mean (geometric coefficient of variation)				
Day 29 AZD5156 gluteal	40.1 (± 55.7)			
Day 181 AZD5156 gluteal	10.7 (± 114.1)			
Day 361 AZD5156 gluteal	1.9 (± 256.8)			
Day 29 AZD5156 thigh	71.0 (± 24.2)			
Day 181 AZD5156 thigh	19.3 (± 107.1)			
Day 361 AZD5156 thigh	3.2 (± 263.6)			
Day 29 AZD3152 gluteal	21.4 (± 53.9)			
Day 181 AZD3152 gluteal	6.2 (± 109.2)			
Day 361 AZD3152 gluteal	1.3 (± 185.8)			
Day 29 AZD3152 thigh	34.9 (± 27.1)			
Day 181 AZD3152 thigh	10.4 (± 107.5)			
Day 361 AZD3152 thigh	2.0 (± 188.8)			
Day 29 AZD1061 gluteal	18.5 (± 61.9)			
Day 181 AZD1061 gluteal	4.5 (± 123.7)			
Day 361 AZD1061 gluteal	0.9 (± 149.5)			
Day 29 AZD1061 thigh	36.0 (± 23.4)			
Day 181 AZD1061 thigh	8.9 (± 106.9)			
Day 361 AZD1061 thigh	1.6 (± 159.3)			

Statistical analyses

No statistical analyses for this end point

Secondary: (Main Cohort) Incidence of ADA to AZD3152 and AZD7442 (EVUSHELD)

End point title	(Main Cohort) Incidence of ADA to AZD3152 and AZD7442 (EVUSHELD)[27]

End point description:

AZD3152 recipients were tested for ADA to AZD3152; AZD7442 recipients were tested for ADA to AZD7442.

End point type	Secondary

End point timeframe:

through Day 361

Notes:

[27] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Safety data was planned to be summarized in a descriptive way without hypothesis testing.

End point values	AZD3152 - Main Cohort	AZD7442 - Main Cohort		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	560	605		
Units: ADA titers				
Treatment-emergent ADA-positive (ADA incidence)	4	3		

Statistical analyses

No statistical analyses for this end point

Secondary: (Sentinel Cohort) Incidence of ADA to AZD5156, AZD3152, and AZD1061

End point title	(Sentinel Cohort) Incidence of ADA to AZD5156, AZD3152, and AZD1061[28]

End point description:

End point type	Secondary

End point timeframe:

through Day 361

Notes:

[28] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Safety data was planned to be summarized in a descriptive way without hypothesis testing.

End point values	AZD5156 - Sentinel Cohort			
Subject group type	Reporting group			
Number of subjects analysed	40			
Units: ADA titers				
Treatment-emergent ADA to AZD5156 - positive	0			
Treatment-emergent ADA to AZD3152 - positive	0			
Treatment-emergent ADA to AZD1061 - positive	0			

Statistical analyses

No statistical analyses for this end point

Secondary: (Main Cohort) ADA titers

End point title	(Main Cohort) ADA titers[29]

End point description:

ADA titers were only available for ADA positive samples.

End point type	Secondary

End point timeframe:

through Day 361

Notes:

[29] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Safety data was planned to be summarized in a descriptive way without hypothesis testing.

End point values	AZD3152 - Main Cohort	AZD7442 - Main Cohort		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	560	605		
Units: ADA titers				
median (full range (min-max))				
Baseline	400 (100 to 1600)	80 (40 to 20480)		
Day 29	200 (100 to 800)	80 (40 to 20480)		
Day 91	150 (100 to 400)	80 (40 to 20480)		
Day 181 (pre-dose)	150 (100 to 400)	80 (40 to 20480)		
Day 210	200 (100 to 800)	120 (40 to 10240)		

Statistical analyses

No statistical analyses for this end point

Secondary: (Main Cohort) AZD1061 and AZD8895 concentrations over time

End point title	(Main Cohort) AZD1061 and AZD8895 concentrations over

End point description:

End point type	Secondary

End point timeframe:

through Day 361

Notes:

[30] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Safety data was planned to be summarized in a descriptive way without hypothesis testing.

End point values	AZD7442 - Main Cohort			
Subject group type	Reporting group			
Number of subjects analysed	780			
Units: mg/L				
geometric mean (geometric coefficient of variation)				
Day 29 AZD1061	30.1 (± 42.4)			
Day 91 AZD1061	17.0 (± 57.3)			
Day 181 AZD1061	7.3 (± 68.0)			
Day 189 AZD1061	6.8 (± 71.3)			
Day 210 AZD1061	5.9 (± 70.3)			
Day 361 AZD1061	1.7 (± 69.4)			

Day 29 AZD8895	31.1 (± 39.0)			
Day 91 AZD8895	18.0 (± 55.7)			
Day 181 AZD8895	8.3 (± 67.8)			
Day 189 AZD8895	7.8 (± 72.2)			
Day 210 AZD8895	6.7 (± 73.4)			
Day 361 AZD8895	2.2 (± 77.6)			

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information	
Timeframe for reporting adverse events: From first dose of study drug until last study visit	
Assessment type	Systematic
Dictionary used	
Dictionary name	MedDRA
Dictionary version	27.0
Reporting groups	
Reporting group title	AZD3152- Main Cohort
Reporting group description: -	
Reporting group title	AZD7442- Main Cohort
Reporting group description: -	
Reporting group title	Placebo- Main Cohort
Reporting group description: -	
Reporting group title	EVUSHELD 300 mg- Sub Study
Reporting group description: -	
Reporting group title	AZD3152 1200 mg- Sub Study
Reporting group description: -	
Reporting group title	AZD5156- Sentinel Cohort
Reporting group description: -	
Reporting group title	Placebo- Sentinel Cohort
Reporting group description: -	

Serious adverse events	AZD3152- Main Cohort	AZD7442- Main Cohort	Placebo- Main Cohort
Total subjects affected by serious adverse events			
subjects affected / exposed	315 / 1671 (18.85%)	222 / 1102 (20.15%)	90 / 561 (16.04%)
number of deaths (all causes)	40	24	6
number of deaths resulting from adverse events	40	24	6
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Acute myeloid leukaemia			
subjects affected / exposed	0 / 1671 (0.00%)	1 / 1102 (0.09%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Acute myeloid leukaemia refractory			
subjects affected / exposed	1 / 1671 (0.06%)	0 / 1102 (0.00%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Anaplastic large cell lymphoma T-			

and null-cell types			
subjects affected / exposed	0 / 1671 (0.00%)	1 / 1102 (0.09%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Adenocarcinoma of colon			
subjects affected / exposed	2 / 1671 (0.12%)	1 / 1102 (0.09%)	1 / 561 (0.18%)
occurrences causally related to treatment / all	0 / 2	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 1
Adenocarcinoma gastric			
subjects affected / exposed	0 / 1671 (0.00%)	0 / 1102 (0.00%)	1 / 561 (0.18%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
B-cell lymphoma			
subjects affected / exposed	1 / 1671 (0.06%)	1 / 1102 (0.09%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
B-cell small lymphocytic lymphoma			
subjects affected / exposed	0 / 1671 (0.00%)	0 / 1102 (0.00%)	1 / 561 (0.18%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bladder cancer			
subjects affected / exposed	0 / 1671 (0.00%)	0 / 1102 (0.00%)	1 / 561 (0.18%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Brain neoplasm			
subjects affected / exposed	0 / 1671 (0.00%)	1 / 1102 (0.09%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bronchial carcinoma			
subjects affected / exposed	0 / 1671 (0.00%)	1 / 1102 (0.09%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Central nervous system lymphoma			

subjects affected / exposed	0 / 1671 (0.00%)	3 / 1102 (0.27%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 3	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 2	0 / 0
Cholangiocarcinoma			
subjects affected / exposed	0 / 1671 (0.00%)	1 / 1102 (0.09%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Chronic lymphocytic leukaemia			
subjects affected / exposed	2 / 1671 (0.12%)	0 / 1102 (0.00%)	1 / 561 (0.18%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Clear cell renal cell carcinoma			
subjects affected / exposed	1 / 1671 (0.06%)	0 / 1102 (0.00%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Follicular lymphoma stage IV			
subjects affected / exposed	0 / 1671 (0.00%)	1 / 1102 (0.09%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Follicular lymphoma			
subjects affected / exposed	1 / 1671 (0.06%)	1 / 1102 (0.09%)	1 / 561 (0.18%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Endometrial cancer metastatic			
subjects affected / exposed	0 / 1671 (0.00%)	0 / 1102 (0.00%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diffuse large B-cell lymphoma			
subjects affected / exposed	2 / 1671 (0.12%)	2 / 1102 (0.18%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Colorectal cancer metastatic			

subjects affected / exposed	1 / 1671 (0.06%)	0 / 1102 (0.00%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Colon cancer metastatic			
subjects affected / exposed	0 / 1671 (0.00%)	1 / 1102 (0.09%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hormone receptor positive breast cancer			
subjects affected / exposed	1 / 1671 (0.06%)	0 / 1102 (0.00%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intestinal adenocarcinoma			
subjects affected / exposed	0 / 1671 (0.00%)	1 / 1102 (0.09%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Invasive ductal breast carcinoma			
subjects affected / exposed	0 / 1671 (0.00%)	0 / 1102 (0.00%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
High-grade B-cell lymphoma			
subjects affected / exposed	1 / 1671 (0.06%)	0 / 1102 (0.00%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatocellular carcinoma			
subjects affected / exposed	0 / 1671 (0.00%)	1 / 1102 (0.09%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Glioma			
subjects affected / exposed	1 / 1671 (0.06%)	0 / 1102 (0.00%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Lung adenocarcinoma			

subjects affected / exposed	0 / 1671 (0.00%)	2 / 1102 (0.18%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Mantle cell lymphoma recurrent			
subjects affected / exposed	1 / 1671 (0.06%)	0 / 1102 (0.00%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Malignant neoplasm progression			
subjects affected / exposed	2 / 1671 (0.12%)	0 / 1102 (0.00%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Malignant melanoma in situ			
subjects affected / exposed	1 / 1671 (0.06%)	0 / 1102 (0.00%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lymphoma			
subjects affected / exposed	0 / 1671 (0.00%)	1 / 1102 (0.09%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Marginal zone lymphoma			
subjects affected / exposed	1 / 1671 (0.06%)	0 / 1102 (0.00%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Myelodysplastic syndrome			
subjects affected / exposed	1 / 1671 (0.06%)	0 / 1102 (0.00%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Non-Hodgkin's lymphoma			
subjects affected / exposed	0 / 1671 (0.00%)	2 / 1102 (0.18%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Non-small cell lung cancer			

subjects affected / exposed	2 / 1671 (0.12%)	0 / 1102 (0.00%)	1 / 561 (0.18%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 2	0 / 0	0 / 0
Non-small cell lung cancer metastatic			
subjects affected / exposed	1 / 1671 (0.06%)	1 / 1102 (0.09%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Oesophageal adenocarcinoma			
subjects affected / exposed	0 / 1671 (0.00%)	1 / 1102 (0.09%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ovarian cancer			
subjects affected / exposed	1 / 1671 (0.06%)	0 / 1102 (0.00%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pancreatic carcinoma			
subjects affected / exposed	0 / 1671 (0.00%)	0 / 1102 (0.00%)	1 / 561 (0.18%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Papillary thyroid cancer			
subjects affected / exposed	1 / 1671 (0.06%)	0 / 1102 (0.00%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Plasma cell myeloma			
subjects affected / exposed	1 / 1671 (0.06%)	1 / 1102 (0.09%)	1 / 561 (0.18%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Rectal cancer stage IV			
subjects affected / exposed	1 / 1671 (0.06%)	0 / 1102 (0.00%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Prostate cancer stage IV			

subjects affected / exposed	0 / 1671 (0.00%)	0 / 1102 (0.00%)	1 / 561 (0.18%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Prostate cancer metastatic			
subjects affected / exposed	1 / 1671 (0.06%)	0 / 1102 (0.00%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Prostate cancer			
subjects affected / exposed	2 / 1671 (0.12%)	1 / 1102 (0.09%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Post transplant lymphoproliferative disorder			
subjects affected / exposed	0 / 1671 (0.00%)	0 / 1102 (0.00%)	1 / 561 (0.18%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Plasma cell myeloma recurrent			
subjects affected / exposed	1 / 1671 (0.06%)	0 / 1102 (0.00%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Squamous cell carcinoma of skin			
subjects affected / exposed	1 / 1671 (0.06%)	0 / 1102 (0.00%)	1 / 561 (0.18%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Squamous cell carcinoma			
subjects affected / exposed	1 / 1671 (0.06%)	0 / 1102 (0.00%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Skin squamous cell carcinoma metastatic			
subjects affected / exposed	1 / 1671 (0.06%)	0 / 1102 (0.00%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal neoplasm			

subjects affected / exposed	0 / 1671 (0.00%)	1 / 1102 (0.09%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal cell carcinoma			
subjects affected / exposed	1 / 1671 (0.06%)	0 / 1102 (0.00%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal cancer metastatic			
subjects affected / exposed	0 / 1671 (0.00%)	1 / 1102 (0.09%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
T-cell lymphoma			
subjects affected / exposed	0 / 1671 (0.00%)	0 / 1102 (0.00%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Uterine leiomyoma			
subjects affected / exposed	1 / 1671 (0.06%)	0 / 1102 (0.00%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Transitional cell carcinoma metastatic			
subjects affected / exposed	0 / 1671 (0.00%)	0 / 1102 (0.00%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Transitional cell carcinoma			
subjects affected / exposed	0 / 1671 (0.00%)	0 / 1102 (0.00%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Throat cancer			
subjects affected / exposed	0 / 1671 (0.00%)	0 / 1102 (0.00%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular disorders			
Aortic dissection			

subjects affected / exposed	0 / 1671 (0.00%)	1 / 1102 (0.09%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Aneurysm ruptured			
subjects affected / exposed	1 / 1671 (0.06%)	0 / 1102 (0.00%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Haematoma			
subjects affected / exposed	1 / 1671 (0.06%)	0 / 1102 (0.00%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dialysis hypotension			
subjects affected / exposed	0 / 1671 (0.00%)	0 / 1102 (0.00%)	1 / 561 (0.18%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Deep vein thrombosis			
subjects affected / exposed	1 / 1671 (0.06%)	0 / 1102 (0.00%)	2 / 561 (0.36%)
occurrences causally related to treatment / all	0 / 3	0 / 0	1 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Brachiocephalic vein thrombosis			
subjects affected / exposed	0 / 1671 (0.00%)	1 / 1102 (0.09%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Arterial thrombosis			
subjects affected / exposed	1 / 1671 (0.06%)	0 / 1102 (0.00%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Aortitis			
subjects affected / exposed	1 / 1671 (0.06%)	0 / 1102 (0.00%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Aortic stenosis			

subjects affected / exposed	1 / 1671 (0.06%)	0 / 1102 (0.00%)	1 / 561 (0.18%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Jugular vein thrombosis			
subjects affected / exposed	1 / 1671 (0.06%)	0 / 1102 (0.00%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypovolaemic shock			
subjects affected / exposed	1 / 1671 (0.06%)	0 / 1102 (0.00%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypotension			
subjects affected / exposed	8 / 1671 (0.48%)	0 / 1102 (0.00%)	1 / 561 (0.18%)
occurrences causally related to treatment / all	0 / 9	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypertensive urgency			
subjects affected / exposed	1 / 1671 (0.06%)	4 / 1102 (0.36%)	2 / 561 (0.36%)
occurrences causally related to treatment / all	0 / 2	1 / 4	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypertensive emergency			
subjects affected / exposed	5 / 1671 (0.30%)	6 / 1102 (0.54%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	1 / 5	0 / 7	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypertensive crisis			
subjects affected / exposed	4 / 1671 (0.24%)	1 / 1102 (0.09%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 4	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypertension			
subjects affected / exposed	4 / 1671 (0.24%)	2 / 1102 (0.18%)	1 / 561 (0.18%)
occurrences causally related to treatment / all	0 / 4	0 / 2	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Orthostatic hypotension			

subjects affected / exposed	1 / 1671 (0.06%)	1 / 1102 (0.09%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Peripheral arterial occlusive disease			
subjects affected / exposed	0 / 1671 (0.00%)	0 / 1102 (0.00%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Peripheral ischaemia			
subjects affected / exposed	1 / 1671 (0.06%)	1 / 1102 (0.09%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Peripheral venous disease			
subjects affected / exposed	1 / 1671 (0.06%)	0 / 1102 (0.00%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Raynaud's phenomenon			
subjects affected / exposed	1 / 1671 (0.06%)	1 / 1102 (0.09%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Shock haemorrhagic			
subjects affected / exposed	2 / 1671 (0.12%)	1 / 1102 (0.09%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Superficial vein thrombosis			
subjects affected / exposed	0 / 1671 (0.00%)	1 / 1102 (0.09%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Venous stenosis			
subjects affected / exposed	1 / 1671 (0.06%)	0 / 1102 (0.00%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Surgical and medical procedures			
Toe amputation			

subjects affected / exposed	0 / 1671 (0.00%)	1 / 1102 (0.09%)	1 / 561 (0.18%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
Adhesion			
subjects affected / exposed	0 / 1671 (0.00%)	1 / 1102 (0.09%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Asthenia			
subjects affected / exposed	2 / 1671 (0.12%)	0 / 1102 (0.00%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Chest pain			
subjects affected / exposed	1 / 1671 (0.06%)	3 / 1102 (0.27%)	1 / 561 (0.18%)
occurrences causally related to treatment / all	0 / 1	0 / 3	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Death			
subjects affected / exposed	2 / 1671 (0.12%)	2 / 1102 (0.18%)	2 / 561 (0.36%)
occurrences causally related to treatment / all	0 / 2	0 / 2	0 / 2
deaths causally related to treatment / all	0 / 2	0 / 2	0 / 2
Gait disturbance			
subjects affected / exposed	0 / 1671 (0.00%)	1 / 1102 (0.09%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Drug withdrawal syndrome			
subjects affected / exposed	0 / 1671 (0.00%)	1 / 1102 (0.09%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General physical health deterioration			
subjects affected / exposed	1 / 1671 (0.06%)	0 / 1102 (0.00%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Injection site necrosis			

subjects affected / exposed	0 / 1671 (0.00%)	0 / 1102 (0.00%)	1 / 561 (0.18%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Multiple organ dysfunction syndrome			
subjects affected / exposed	1 / 1671 (0.06%)	0 / 1102 (0.00%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Non-cardiac chest pain			
subjects affected / exposed	2 / 1671 (0.12%)	2 / 1102 (0.18%)	1 / 561 (0.18%)
occurrences causally related to treatment / all	0 / 2	0 / 2	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyrexia			
subjects affected / exposed	5 / 1671 (0.30%)	3 / 1102 (0.27%)	1 / 561 (0.18%)
occurrences causally related to treatment / all	0 / 5	0 / 3	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Systemic inflammatory response syndrome			
subjects affected / exposed	1 / 1671 (0.06%)	0 / 1102 (0.00%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Generalised oedema			
subjects affected / exposed	0 / 1671 (0.00%)	1 / 1102 (0.09%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Immune system disorders			
Anaphylactic reaction			
subjects affected / exposed	1 / 1671 (0.06%)	0 / 1102 (0.00%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Kidney transplant rejection			
subjects affected / exposed	1 / 1671 (0.06%)	1 / 1102 (0.09%)	1 / 561 (0.18%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infusion related hypersensitivity reaction			

subjects affected / exposed	1 / 1671 (0.06%)	0 / 1102 (0.00%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypersensitivity			
subjects affected / exposed	0 / 1671 (0.00%)	0 / 1102 (0.00%)	1 / 561 (0.18%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Graft versus host disease			
subjects affected / exposed	1 / 1671 (0.06%)	0 / 1102 (0.00%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Drug hypersensitivity			
subjects affected / exposed	0 / 1671 (0.00%)	1 / 1102 (0.09%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cytokine release syndrome			
subjects affected / exposed	1 / 1671 (0.06%)	0 / 1102 (0.00%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Anti-neutrophil cytoplasmic antibody positive vasculitis			
subjects affected / exposed	0 / 1671 (0.00%)	1 / 1102 (0.09%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Transplant rejection			
subjects affected / exposed	0 / 1671 (0.00%)	0 / 1102 (0.00%)	1 / 561 (0.18%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Liver transplant rejection			
subjects affected / exposed	0 / 1671 (0.00%)	1 / 1102 (0.09%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Reproductive system and breast disorders			

Cervical dysplasia			
subjects affected / exposed	1 / 1671 (0.06%)	0 / 1102 (0.00%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cystocele			
subjects affected / exposed	0 / 1671 (0.00%)	1 / 1102 (0.09%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Endometrial hyperplasia			
subjects affected / exposed	1 / 1671 (0.06%)	0 / 1102 (0.00%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ovarian cyst			
subjects affected / exposed	1 / 1671 (0.06%)	0 / 1102 (0.00%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pelvic pain			
subjects affected / exposed	1 / 1671 (0.06%)	1 / 1102 (0.09%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Prostatitis			
subjects affected / exposed	1 / 1671 (0.06%)	0 / 1102 (0.00%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Aspiration			
subjects affected / exposed	0 / 1671 (0.00%)	1 / 1102 (0.09%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Acute respiratory failure			
subjects affected / exposed	7 / 1671 (0.42%)	9 / 1102 (0.82%)	3 / 561 (0.53%)
occurrences causally related to treatment / all	0 / 7	0 / 11	0 / 3
deaths causally related to treatment / all	0 / 2	0 / 3	0 / 0

Acute pulmonary oedema			
subjects affected / exposed	2 / 1671 (0.12%)	1 / 1102 (0.09%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	1 / 2	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Asthma			
subjects affected / exposed	1 / 1671 (0.06%)	0 / 1102 (0.00%)	1 / 561 (0.18%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Chronic obstructive pulmonary disease			
subjects affected / exposed	5 / 1671 (0.30%)	0 / 1102 (0.00%)	1 / 561 (0.18%)
occurrences causally related to treatment / all	0 / 5	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Bronchiectasis			
subjects affected / exposed	1 / 1671 (0.06%)	0 / 1102 (0.00%)	1 / 561 (0.18%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bronchial hyperreactivity			
subjects affected / exposed	0 / 1671 (0.00%)	1 / 1102 (0.09%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Interstitial lung disease			
subjects affected / exposed	0 / 1671 (0.00%)	1 / 1102 (0.09%)	1 / 561 (0.18%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypoxia			
subjects affected / exposed	1 / 1671 (0.06%)	0 / 1102 (0.00%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haemothorax			
subjects affected / exposed	0 / 1671 (0.00%)	1 / 1102 (0.09%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haemoptysis			

subjects affected / exposed	2 / 1671 (0.12%)	0 / 1102 (0.00%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Dyspnoea			
subjects affected / exposed	5 / 1671 (0.30%)	3 / 1102 (0.27%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 5	0 / 3	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Chronic rhinosinusitis with nasal polyps			
subjects affected / exposed	1 / 1671 (0.06%)	0 / 1102 (0.00%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pleural effusion			
subjects affected / exposed	3 / 1671 (0.18%)	3 / 1102 (0.27%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 5	0 / 3	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumothorax			
subjects affected / exposed	1 / 1671 (0.06%)	1 / 1102 (0.09%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary embolism			
subjects affected / exposed	8 / 1671 (0.48%)	0 / 1102 (0.00%)	1 / 561 (0.18%)
occurrences causally related to treatment / all	1 / 8	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Organising pneumonia			
subjects affected / exposed	0 / 1671 (0.00%)	1 / 1102 (0.09%)	2 / 561 (0.36%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Malignant pleural effusion			
subjects affected / exposed	0 / 1671 (0.00%)	1 / 1102 (0.09%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary fibrosis			

subjects affected / exposed	1 / 1671 (0.06%)	0 / 1102 (0.00%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Lupus pleurisy			
subjects affected / exposed	0 / 1671 (0.00%)	1 / 1102 (0.09%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary hypertension			
subjects affected / exposed	1 / 1671 (0.06%)	2 / 1102 (0.18%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory failure			
subjects affected / exposed	2 / 1671 (0.12%)	3 / 1102 (0.27%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 3	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory arrest			
subjects affected / exposed	0 / 1671 (0.00%)	1 / 1102 (0.09%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Pulmonary oedema			
subjects affected / exposed	7 / 1671 (0.42%)	4 / 1102 (0.36%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 7	0 / 4	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary infarction			
subjects affected / exposed	0 / 1671 (0.00%)	0 / 1102 (0.00%)	1 / 561 (0.18%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary haemorrhage			
subjects affected / exposed	0 / 1671 (0.00%)	1 / 1102 (0.09%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Psychiatric disorders			
Alcohol withdrawal syndrome			

subjects affected / exposed	1 / 1671 (0.06%)	0 / 1102 (0.00%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bipolar disorder			
subjects affected / exposed	0 / 1671 (0.00%)	1 / 1102 (0.09%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Psychotic disorder			
subjects affected / exposed	0 / 1671 (0.00%)	0 / 1102 (0.00%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Post-traumatic stress disorder			
subjects affected / exposed	0 / 1671 (0.00%)	1 / 1102 (0.09%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Mental status changes			
subjects affected / exposed	1 / 1671 (0.06%)	3 / 1102 (0.27%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 3	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Suicide attempt			
subjects affected / exposed	1 / 1671 (0.06%)	0 / 1102 (0.00%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Product issues			
Device malfunction			
subjects affected / exposed	0 / 1671 (0.00%)	1 / 1102 (0.09%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Investigations			
International normalised ratio increased			
subjects affected / exposed	1 / 1671 (0.06%)	1 / 1102 (0.09%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Influenza A virus test positive			
subjects affected / exposed	0 / 1671 (0.00%)	1 / 1102 (0.09%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Anticoagulation drug level above therapeutic			
subjects affected / exposed	1 / 1671 (0.06%)	0 / 1102 (0.00%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Troponin increased			
subjects affected / exposed	1 / 1671 (0.06%)	1 / 1102 (0.09%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
White blood cell count decreased			
subjects affected / exposed	1 / 1671 (0.06%)	0 / 1102 (0.00%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
Accidental overdose			
subjects affected / exposed	0 / 1671 (0.00%)	1 / 1102 (0.09%)	1 / 561 (0.18%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Anaemia postoperative			
subjects affected / exposed	1 / 1671 (0.06%)	1 / 1102 (0.09%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Acetabulum fracture			
subjects affected / exposed	1 / 1671 (0.06%)	0 / 1102 (0.00%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Anastomotic ulcer			
subjects affected / exposed	0 / 1671 (0.00%)	1 / 1102 (0.09%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Arteriovenous fistula thrombosis			
subjects affected / exposed	1 / 1671 (0.06%)	0 / 1102 (0.00%)	1 / 561 (0.18%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Arteriovenous fistula site complication			
subjects affected / exposed	2 / 1671 (0.12%)	1 / 1102 (0.09%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Arteriovenous fistula occlusion			
subjects affected / exposed	0 / 1671 (0.00%)	1 / 1102 (0.09%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ankle fracture			
subjects affected / exposed	2 / 1671 (0.12%)	1 / 1102 (0.09%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Arteriovenous graft thrombosis			
subjects affected / exposed	1 / 1671 (0.06%)	2 / 1102 (0.18%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Complications of transplanted kidney			
subjects affected / exposed	1 / 1671 (0.06%)	0 / 1102 (0.00%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Comminuted fracture			
subjects affected / exposed	1 / 1671 (0.06%)	0 / 1102 (0.00%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cervical vertebral fracture			
subjects affected / exposed	1 / 1671 (0.06%)	0 / 1102 (0.00%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Burns second degree			

subjects affected / exposed	0 / 1671 (0.00%)	0 / 1102 (0.00%)	1 / 561 (0.18%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cystitis radiation			
subjects affected / exposed	0 / 1671 (0.00%)	1 / 1102 (0.09%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Deep vein thrombosis postoperative			
subjects affected / exposed	0 / 1671 (0.00%)	0 / 1102 (0.00%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Fall			
subjects affected / exposed	0 / 1671 (0.00%)	1 / 1102 (0.09%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Femoral neck fracture			
subjects affected / exposed	2 / 1671 (0.12%)	0 / 1102 (0.00%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Femur fracture			
subjects affected / exposed	1 / 1671 (0.06%)	0 / 1102 (0.00%)	1 / 561 (0.18%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Fibula fracture			
subjects affected / exposed	0 / 1671 (0.00%)	1 / 1102 (0.09%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Foot fracture			
subjects affected / exposed	1 / 1671 (0.06%)	1 / 1102 (0.09%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal stoma complication			

subjects affected / exposed	0 / 1671 (0.00%)	1 / 1102 (0.09%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Incisional hernia, obstructive			
subjects affected / exposed	1 / 1671 (0.06%)	0 / 1102 (0.00%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyphaema			
subjects affected / exposed	0 / 1671 (0.00%)	1 / 1102 (0.09%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Humerus fracture			
subjects affected / exposed	0 / 1671 (0.00%)	1 / 1102 (0.09%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrostomy tube site complication			
subjects affected / exposed	1 / 1671 (0.06%)	0 / 1102 (0.00%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Graft haemorrhage			
subjects affected / exposed	0 / 1671 (0.00%)	1 / 1102 (0.09%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hip fracture			
subjects affected / exposed	2 / 1671 (0.12%)	0 / 1102 (0.00%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intentional overdose			
subjects affected / exposed	0 / 1671 (0.00%)	1 / 1102 (0.09%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Post procedural complication			

subjects affected / exposed	1 / 1671 (0.06%)	0 / 1102 (0.00%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Post procedural bile leak			
subjects affected / exposed	1 / 1671 (0.06%)	0 / 1102 (0.00%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pelvic fracture			
subjects affected / exposed	1 / 1671 (0.06%)	1 / 1102 (0.09%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Multiple fractures			
subjects affected / exposed	0 / 1671 (0.00%)	1 / 1102 (0.09%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lower limb fracture			
subjects affected / exposed	0 / 1671 (0.00%)	1 / 1102 (0.09%)	1 / 561 (0.18%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Limb injury			
subjects affected / exposed	1 / 1671 (0.06%)	0 / 1102 (0.00%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Post procedural fever			
subjects affected / exposed	1 / 1671 (0.06%)	0 / 1102 (0.00%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Post procedural haemorrhage			
subjects affected / exposed	2 / 1671 (0.12%)	0 / 1102 (0.00%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Postoperative respiratory failure			

subjects affected / exposed	0 / 1671 (0.00%)	1 / 1102 (0.09%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Procedural haemorrhage			
subjects affected / exposed	1 / 1671 (0.06%)	0 / 1102 (0.00%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Radius fracture			
subjects affected / exposed	2 / 1671 (0.12%)	0 / 1102 (0.00%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal transplant failure			
subjects affected / exposed	0 / 1671 (0.00%)	1 / 1102 (0.09%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rib fracture			
subjects affected / exposed	1 / 1671 (0.06%)	0 / 1102 (0.00%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Spinal compression fracture			
subjects affected / exposed	0 / 1671 (0.00%)	1 / 1102 (0.09%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Spinal fracture			
subjects affected / exposed	1 / 1671 (0.06%)	0 / 1102 (0.00%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Spleen contusion			
subjects affected / exposed	1 / 1671 (0.06%)	0 / 1102 (0.00%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Subcutaneous haematoma			

subjects affected / exposed	1 / 1671 (0.06%)	0 / 1102 (0.00%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Subdural haemorrhage			
subjects affected / exposed	1 / 1671 (0.06%)	0 / 1102 (0.00%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tendon injury			
subjects affected / exposed	1 / 1671 (0.06%)	0 / 1102 (0.00%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tendon rupture			
subjects affected / exposed	1 / 1671 (0.06%)	0 / 1102 (0.00%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Upper limb fracture			
subjects affected / exposed	0 / 1671 (0.00%)	0 / 1102 (0.00%)	1 / 561 (0.18%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ulna fracture			
subjects affected / exposed	0 / 1671 (0.00%)	1 / 1102 (0.09%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tibia fracture			
subjects affected / exposed	1 / 1671 (0.06%)	0 / 1102 (0.00%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular access site thrombosis			
subjects affected / exposed	1 / 1671 (0.06%)	0 / 1102 (0.00%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Wound dehiscence			

subjects affected / exposed	1 / 1671 (0.06%)	0 / 1102 (0.00%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular graft occlusion			
subjects affected / exposed	0 / 1671 (0.00%)	1 / 1102 (0.09%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular graft complication			
subjects affected / exposed	0 / 1671 (0.00%)	1 / 1102 (0.09%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Congenital, familial and genetic disorders			
Haemorrhagic arteriovenous malformation			
subjects affected / exposed	1 / 1671 (0.06%)	0 / 1102 (0.00%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
Acute right ventricular failure			
subjects affected / exposed	1 / 1671 (0.06%)	0 / 1102 (0.00%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Acute myocardial infarction			
subjects affected / exposed	15 / 1671 (0.90%)	11 / 1102 (1.00%)	3 / 561 (0.53%)
occurrences causally related to treatment / all	0 / 18	0 / 12	0 / 3
deaths causally related to treatment / all	0 / 1	0 / 3	0 / 0
Acute left ventricular failure			
subjects affected / exposed	3 / 1671 (0.18%)	2 / 1102 (0.18%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 3	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Acute coronary syndrome			
subjects affected / exposed	1 / 1671 (0.06%)	1 / 1102 (0.09%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0

Angina pectoris			
subjects affected / exposed	1 / 1671 (0.06%)	2 / 1102 (0.18%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Arteriosclerosis coronary artery			
subjects affected / exposed	0 / 1671 (0.00%)	0 / 1102 (0.00%)	1 / 561 (0.18%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Angina unstable			
subjects affected / exposed	0 / 1671 (0.00%)	0 / 1102 (0.00%)	1 / 561 (0.18%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Atrial fibrillation			
subjects affected / exposed	12 / 1671 (0.72%)	7 / 1102 (0.64%)	2 / 561 (0.36%)
occurrences causally related to treatment / all	0 / 13	0 / 8	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Atrial flutter			
subjects affected / exposed	1 / 1671 (0.06%)	2 / 1102 (0.18%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Atrioventricular block complete			
subjects affected / exposed	0 / 1671 (0.00%)	1 / 1102 (0.09%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Atrioventricular block second degree			
subjects affected / exposed	1 / 1671 (0.06%)	1 / 1102 (0.09%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bradycardia			
subjects affected / exposed	1 / 1671 (0.06%)	1 / 1102 (0.09%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac failure			

subjects affected / exposed	1 / 1671 (0.06%)	2 / 1102 (0.18%)	2 / 561 (0.36%)
occurrences causally related to treatment / all	0 / 2	0 / 2	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac arrest			
subjects affected / exposed	7 / 1671 (0.42%)	2 / 1102 (0.18%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 7	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 7	0 / 1	0 / 0
Cardiac failure acute			
subjects affected / exposed	8 / 1671 (0.48%)	4 / 1102 (0.36%)	1 / 561 (0.18%)
occurrences causally related to treatment / all	0 / 9	0 / 4	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardio-respiratory arrest			
subjects affected / exposed	1 / 1671 (0.06%)	1 / 1102 (0.09%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 1	0 / 0
Cardiac valve disease			
subjects affected / exposed	1 / 1671 (0.06%)	0 / 1102 (0.00%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac failure congestive			
subjects affected / exposed	11 / 1671 (0.66%)	10 / 1102 (0.91%)	2 / 561 (0.36%)
occurrences causally related to treatment / all	0 / 12	0 / 11	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiogenic shock			
subjects affected / exposed	1 / 1671 (0.06%)	0 / 1102 (0.00%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Coronary artery disease			
subjects affected / exposed	3 / 1671 (0.18%)	1 / 1102 (0.09%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 3	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Heart failure with preserved ejection fraction			

subjects affected / exposed	1 / 1671 (0.06%)	1 / 1102 (0.09%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Heart failure with reduced ejection fraction			
subjects affected / exposed	1 / 1671 (0.06%)	1 / 1102 (0.09%)	3 / 561 (0.53%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypertensive heart disease			
subjects affected / exposed	1 / 1671 (0.06%)	0 / 1102 (0.00%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Left ventricular dysfunction			
subjects affected / exposed	0 / 1671 (0.00%)	1 / 1102 (0.09%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Mitral valve incompetence			
subjects affected / exposed	1 / 1671 (0.06%)	1 / 1102 (0.09%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Myocardial infarction			
subjects affected / exposed	4 / 1671 (0.24%)	2 / 1102 (0.18%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 4	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 1	0 / 0
Pericardial effusion			
subjects affected / exposed	2 / 1671 (0.12%)	1 / 1102 (0.09%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tachycardia			
subjects affected / exposed	0 / 1671 (0.00%)	1 / 1102 (0.09%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Supraventricular tachycardia			

subjects affected / exposed	1 / 1671 (0.06%)	1 / 1102 (0.09%)	1 / 561 (0.18%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pericarditis			
subjects affected / exposed	0 / 1671 (0.00%)	1 / 1102 (0.09%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ventricular extrasystoles			
subjects affected / exposed	1 / 1671 (0.06%)	0 / 1102 (0.00%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ventricular fibrillation			
subjects affected / exposed	0 / 1671 (0.00%)	1 / 1102 (0.09%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ventricular tachyarrhythmia			
subjects affected / exposed	1 / 1671 (0.06%)	0 / 1102 (0.00%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ventricular tachycardia			
subjects affected / exposed	3 / 1671 (0.18%)	0 / 1102 (0.00%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 3	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Brain stem haemorrhage			
subjects affected / exposed	1 / 1671 (0.06%)	0 / 1102 (0.00%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Brain injury			
subjects affected / exposed	0 / 1671 (0.00%)	2 / 1102 (0.18%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Ataxia			

subjects affected / exposed	1 / 1671 (0.06%)	0 / 1102 (0.00%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Aphasia			
subjects affected / exposed	0 / 1671 (0.00%)	1 / 1102 (0.09%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Altered state of consciousness			
subjects affected / exposed	0 / 1671 (0.00%)	0 / 1102 (0.00%)	1 / 561 (0.18%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Central nervous system lupus			
subjects affected / exposed	0 / 1671 (0.00%)	1 / 1102 (0.09%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cauda equina syndrome			
subjects affected / exposed	0 / 1671 (0.00%)	0 / 1102 (0.00%)	1 / 561 (0.18%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Carotid artery disease			
subjects affected / exposed	1 / 1671 (0.06%)	0 / 1102 (0.00%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Carotid arteriosclerosis			
subjects affected / exposed	1 / 1671 (0.06%)	0 / 1102 (0.00%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Brain stem stroke			
subjects affected / exposed	1 / 1671 (0.06%)	0 / 1102 (0.00%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Brain stem infarction			

subjects affected / exposed	1 / 1671 (0.06%)	0 / 1102 (0.00%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diabetic neuropathy			
subjects affected / exposed	0 / 1671 (0.00%)	1 / 1102 (0.09%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cervical radiculopathy			
subjects affected / exposed	0 / 1671 (0.00%)	1 / 1102 (0.09%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cerebrovascular accident			
subjects affected / exposed	6 / 1671 (0.36%)	0 / 1102 (0.00%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	1 / 6	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Cerebral microinfarction			
subjects affected / exposed	1 / 1671 (0.06%)	0 / 1102 (0.00%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cerebral infarction			
subjects affected / exposed	1 / 1671 (0.06%)	0 / 1102 (0.00%)	1 / 561 (0.18%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cerebral haemorrhage			
subjects affected / exposed	1 / 1671 (0.06%)	0 / 1102 (0.00%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Embolic stroke			
subjects affected / exposed	1 / 1671 (0.06%)	0 / 1102 (0.00%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haemorrhagic stroke			

subjects affected / exposed	1 / 1671 (0.06%)	0 / 1102 (0.00%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Headache			
subjects affected / exposed	0 / 1671 (0.00%)	0 / 1102 (0.00%)	2 / 561 (0.36%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Focal dyscognitive seizures			
subjects affected / exposed	1 / 1671 (0.06%)	0 / 1102 (0.00%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Facial paralysis			
subjects affected / exposed	1 / 1671 (0.06%)	0 / 1102 (0.00%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haemorrhage intracranial			
subjects affected / exposed	1 / 1671 (0.06%)	0 / 1102 (0.00%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Encephalopathy			
subjects affected / exposed	2 / 1671 (0.12%)	1 / 1102 (0.09%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Epilepsy			
subjects affected / exposed	0 / 1671 (0.00%)	1 / 1102 (0.09%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Idiopathic intracranial hypertension			
subjects affected / exposed	1 / 1671 (0.06%)	0 / 1102 (0.00%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intracranial aneurysm			

subjects affected / exposed	1 / 1671 (0.06%)	0 / 1102 (0.00%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ischaemic stroke			
subjects affected / exposed	2 / 1671 (0.12%)	1 / 1102 (0.09%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Migraine			
subjects affected / exposed	0 / 1671 (0.00%)	1 / 1102 (0.09%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolic encephalopathy			
subjects affected / exposed	3 / 1671 (0.18%)	1 / 1102 (0.09%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 4	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Multiple sclerosis relapse			
subjects affected / exposed	2 / 1671 (0.12%)	0 / 1102 (0.00%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Myasthenia gravis			
subjects affected / exposed	0 / 1671 (0.00%)	0 / 1102 (0.00%)	1 / 561 (0.18%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Myasthenia gravis crisis			
subjects affected / exposed	0 / 1671 (0.00%)	1 / 1102 (0.09%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Myelopathy			
subjects affected / exposed	1 / 1671 (0.06%)	0 / 1102 (0.00%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nerve compression			

subjects affected / exposed	0 / 1671 (0.00%)	1 / 1102 (0.09%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Neurotoxicity			
subjects affected / exposed	0 / 1671 (0.00%)	1 / 1102 (0.09%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Partial seizures			
subjects affected / exposed	0 / 1671 (0.00%)	1 / 1102 (0.09%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Multiple sclerosis			
subjects affected / exposed	1 / 1671 (0.06%)	0 / 1102 (0.00%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Toxic encephalopathy			
subjects affected / exposed	0 / 1671 (0.00%)	1 / 1102 (0.09%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tension headache			
subjects affected / exposed	1 / 1671 (0.06%)	0 / 1102 (0.00%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Syncope			
subjects affected / exposed	7 / 1671 (0.42%)	1 / 1102 (0.09%)	1 / 561 (0.18%)
occurrences causally related to treatment / all	0 / 7	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Phrenic nerve paralysis			
subjects affected / exposed	0 / 1671 (0.00%)	1 / 1102 (0.09%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sciatica			

subjects affected / exposed	0 / 1671 (0.00%)	2 / 1102 (0.18%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Seizure			
subjects affected / exposed	3 / 1671 (0.18%)	2 / 1102 (0.18%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 3	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
VIth nerve paralysis			
subjects affected / exposed	1 / 1671 (0.06%)	0 / 1102 (0.00%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Trigeminal neuralgia			
subjects affected / exposed	1 / 1671 (0.06%)	0 / 1102 (0.00%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Transient ischaemic attack			
subjects affected / exposed	1 / 1671 (0.06%)	2 / 1102 (0.18%)	1 / 561 (0.18%)
occurrences causally related to treatment / all	0 / 1	0 / 2	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood and lymphatic system disorders			
Agranulocytosis			
subjects affected / exposed	0 / 1671 (0.00%)	0 / 1102 (0.00%)	1 / 561 (0.18%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Anaemia			
subjects affected / exposed	3 / 1671 (0.18%)	6 / 1102 (0.54%)	2 / 561 (0.36%)
occurrences causally related to treatment / all	0 / 4	0 / 6	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Autoimmune neutropenia			
subjects affected / exposed	0 / 1671 (0.00%)	1 / 1102 (0.09%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bicytopenia			

subjects affected / exposed	0 / 1671 (0.00%)	1 / 1102 (0.09%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Febrile neutropenia			
subjects affected / exposed	6 / 1671 (0.36%)	5 / 1102 (0.45%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 7	0 / 7	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood loss anaemia			
subjects affected / exposed	1 / 1671 (0.06%)	1 / 1102 (0.09%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Immune-mediated pancytopenia			
subjects affected / exposed	0 / 1671 (0.00%)	0 / 1102 (0.00%)	1 / 561 (0.18%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Iron deficiency anaemia			
subjects affected / exposed	1 / 1671 (0.06%)	0 / 1102 (0.00%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Neutropenia			
subjects affected / exposed	1 / 1671 (0.06%)	2 / 1102 (0.18%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nephrogenic anaemia			
subjects affected / exposed	2 / 1671 (0.12%)	1 / 1102 (0.09%)	1 / 561 (0.18%)
occurrences causally related to treatment / all	0 / 2	0 / 2	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pancytopenia			
subjects affected / exposed	1 / 1671 (0.06%)	0 / 1102 (0.00%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Splenic infarction			

subjects affected / exposed	0 / 1671 (0.00%)	1 / 1102 (0.09%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Thrombocytopenia			
subjects affected / exposed	0 / 1671 (0.00%)	1 / 1102 (0.09%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Eye disorders			
Glaucoma			
subjects affected / exposed	1 / 1671 (0.06%)	0 / 1102 (0.00%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diabetic retinal oedema			
subjects affected / exposed	0 / 1671 (0.00%)	1 / 1102 (0.09%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cataract			
subjects affected / exposed	0 / 1671 (0.00%)	1 / 1102 (0.09%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Retinal vein occlusion			
subjects affected / exposed	0 / 1671 (0.00%)	1 / 1102 (0.09%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Colitis			
subjects affected / exposed	5 / 1671 (0.30%)	0 / 1102 (0.00%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 5	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ascites			
subjects affected / exposed	3 / 1671 (0.18%)	0 / 1102 (0.00%)	2 / 561 (0.36%)
occurrences causally related to treatment / all	0 / 3	0 / 0	0 / 4
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Abdominal wall cyst			

subjects affected / exposed	0 / 1671 (0.00%)	1 / 1102 (0.09%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Abdominal pain upper			
subjects affected / exposed	1 / 1671 (0.06%)	0 / 1102 (0.00%)	1 / 561 (0.18%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Abdominal pain			
subjects affected / exposed	2 / 1671 (0.12%)	0 / 1102 (0.00%)	1 / 561 (0.18%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Abdominal hernia			
subjects affected / exposed	1 / 1671 (0.06%)	0 / 1102 (0.00%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Abdominal adhesions			
subjects affected / exposed	1 / 1671 (0.06%)	0 / 1102 (0.00%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Colitis ischaemic			
subjects affected / exposed	0 / 1671 (0.00%)	1 / 1102 (0.09%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Duodenal ulcer haemorrhage			
subjects affected / exposed	0 / 1671 (0.00%)	0 / 1102 (0.00%)	1 / 561 (0.18%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Duodenal stenosis			
subjects affected / exposed	0 / 1671 (0.00%)	0 / 1102 (0.00%)	1 / 561 (0.18%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diverticulum intestinal haemorrhagic			

subjects affected / exposed	1 / 1671 (0.06%)	0 / 1102 (0.00%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diverticulum intestinal			
subjects affected / exposed	0 / 1671 (0.00%)	0 / 1102 (0.00%)	1 / 561 (0.18%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diarrhoea			
subjects affected / exposed	2 / 1671 (0.12%)	0 / 1102 (0.00%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Colitis ulcerative			
subjects affected / exposed	0 / 1671 (0.00%)	1 / 1102 (0.09%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastritis haemorrhagic			
subjects affected / exposed	0 / 1671 (0.00%)	0 / 1102 (0.00%)	1 / 561 (0.18%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastritis			
subjects affected / exposed	1 / 1671 (0.06%)	1 / 1102 (0.09%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Food poisoning			
subjects affected / exposed	1 / 1671 (0.06%)	0 / 1102 (0.00%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Fistula of small intestine			
subjects affected / exposed	0 / 1671 (0.00%)	0 / 1102 (0.00%)	1 / 561 (0.18%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Femoral hernia			

subjects affected / exposed	1 / 1671 (0.06%)	0 / 1102 (0.00%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal haemorrhage			
subjects affected / exposed	3 / 1671 (0.18%)	1 / 1102 (0.09%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 3	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Faecaloma			
subjects affected / exposed	1 / 1671 (0.06%)	0 / 1102 (0.00%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal polyp haemorrhage			
subjects affected / exposed	0 / 1671 (0.00%)	1 / 1102 (0.09%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal pain			
subjects affected / exposed	0 / 1671 (0.00%)	1 / 1102 (0.09%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haematemesis			
subjects affected / exposed	0 / 1671 (0.00%)	1 / 1102 (0.09%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Inguinal hernia			
subjects affected / exposed	2 / 1671 (0.12%)	0 / 1102 (0.00%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Impaired gastric emptying			
subjects affected / exposed	1 / 1671 (0.06%)	1 / 1102 (0.09%)	1 / 561 (0.18%)
occurrences causally related to treatment / all	0 / 1	0 / 2	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ileus			

subjects affected / exposed	1 / 1671 (0.06%)	0 / 1102 (0.00%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hiatus hernia			
subjects affected / exposed	1 / 1671 (0.06%)	0 / 1102 (0.00%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Large intestine perforation			
subjects affected / exposed	1 / 1671 (0.06%)	0 / 1102 (0.00%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Large intestinal ulcer perforation			
subjects affected / exposed	0 / 1671 (0.00%)	1 / 1102 (0.09%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intra-abdominal haemorrhage			
subjects affected / exposed	1 / 1671 (0.06%)	0 / 1102 (0.00%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intestinal perforation			
subjects affected / exposed	0 / 1671 (0.00%)	1 / 1102 (0.09%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intestinal obstruction			
subjects affected / exposed	0 / 1671 (0.00%)	1 / 1102 (0.09%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Internal hernia			
subjects affected / exposed	0 / 1671 (0.00%)	0 / 1102 (0.00%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Oesophagitis			

subjects affected / exposed	0 / 1671 (0.00%)	2 / 1102 (0.18%)	1 / 561 (0.18%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Oesophageal stenosis			
subjects affected / exposed	1 / 1671 (0.06%)	0 / 1102 (0.00%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Oedematous pancreatitis			
subjects affected / exposed	0 / 1671 (0.00%)	0 / 1102 (0.00%)	1 / 561 (0.18%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Obstructive pancreatitis			
subjects affected / exposed	0 / 1671 (0.00%)	1 / 1102 (0.09%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nausea			
subjects affected / exposed	1 / 1671 (0.06%)	0 / 1102 (0.00%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lower gastrointestinal haemorrhage			
subjects affected / exposed	1 / 1671 (0.06%)	1 / 1102 (0.09%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Oral macule			
subjects affected / exposed	1 / 1671 (0.06%)	0 / 1102 (0.00%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pancreatitis acute			
subjects affected / exposed	1 / 1671 (0.06%)	0 / 1102 (0.00%)	1 / 561 (0.18%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 4
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pancreatitis necrotising			

subjects affected / exposed	1 / 1671 (0.06%)	0 / 1102 (0.00%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Retroperitoneal haematoma			
subjects affected / exposed	2 / 1671 (0.12%)	0 / 1102 (0.00%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Small intestinal obstruction			
subjects affected / exposed	1 / 1671 (0.06%)	3 / 1102 (0.27%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 3	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Stomatitis			
subjects affected / exposed	0 / 1671 (0.00%)	1 / 1102 (0.09%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Umbilical hernia			
subjects affected / exposed	0 / 1671 (0.00%)	1 / 1102 (0.09%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Upper gastrointestinal haemorrhage			
subjects affected / exposed	4 / 1671 (0.24%)	1 / 1102 (0.09%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 4	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Volvulus of small bowel			
subjects affected / exposed	1 / 1671 (0.06%)	0 / 1102 (0.00%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vomiting			
subjects affected / exposed	3 / 1671 (0.18%)	0 / 1102 (0.00%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 3	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatobiliary disorders			
Cholecystitis acute			

subjects affected / exposed	4 / 1671 (0.24%)	1 / 1102 (0.09%)	1 / 561 (0.18%)
occurrences causally related to treatment / all	0 / 4	0 / 1	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cholecystitis			
subjects affected / exposed	1 / 1671 (0.06%)	0 / 1102 (0.00%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Biliary obstruction			
subjects affected / exposed	0 / 1671 (0.00%)	1 / 1102 (0.09%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Autoimmune hepatitis			
subjects affected / exposed	0 / 1671 (0.00%)	0 / 1102 (0.00%)	1 / 561 (0.18%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Acute cholecystitis necrotic			
subjects affected / exposed	0 / 1671 (0.00%)	0 / 1102 (0.00%)	1 / 561 (0.18%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cholecystitis chronic			
subjects affected / exposed	0 / 1671 (0.00%)	1 / 1102 (0.09%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cholelithiasis			
subjects affected / exposed	1 / 1671 (0.06%)	0 / 1102 (0.00%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Drug-induced liver injury			
subjects affected / exposed	1 / 1671 (0.06%)	0 / 1102 (0.00%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Jaundice cholestatic			

subjects affected / exposed	1 / 1671 (0.06%)	1 / 1102 (0.09%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatitis toxic			
subjects affected / exposed	0 / 1671 (0.00%)	0 / 1102 (0.00%)	1 / 561 (0.18%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatitis acute			
subjects affected / exposed	1 / 1671 (0.06%)	1 / 1102 (0.09%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatic cirrhosis			
subjects affected / exposed	1 / 1671 (0.06%)	0 / 1102 (0.00%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Skin and subcutaneous tissue disorders			
Pruritus			
subjects affected / exposed	0 / 1671 (0.00%)	1 / 1102 (0.09%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Erythema nodosum			
subjects affected / exposed	0 / 1671 (0.00%)	1 / 1102 (0.09%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diabetic foot			
subjects affected / exposed	2 / 1671 (0.12%)	0 / 1102 (0.00%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Skin mass			
subjects affected / exposed	1 / 1671 (0.06%)	0 / 1102 (0.00%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			

Bladder perforation			
subjects affected / exposed	0 / 1671 (0.00%)	1 / 1102 (0.09%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Azotaemia			
subjects affected / exposed	0 / 1671 (0.00%)	1 / 1102 (0.09%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Acute kidney injury			
subjects affected / exposed	11 / 1671 (0.66%)	8 / 1102 (0.73%)	4 / 561 (0.71%)
occurrences causally related to treatment / all	0 / 11	0 / 10	0 / 5
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Chronic kidney disease			
subjects affected / exposed	0 / 1671 (0.00%)	0 / 1102 (0.00%)	1 / 561 (0.18%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nephrolithiasis			
subjects affected / exposed	1 / 1671 (0.06%)	0 / 1102 (0.00%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nephrotic syndrome			
subjects affected / exposed	0 / 1671 (0.00%)	1 / 1102 (0.09%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal artery stenosis			
subjects affected / exposed	0 / 1671 (0.00%)	1 / 1102 (0.09%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cystitis haemorrhagic			
subjects affected / exposed	1 / 1671 (0.06%)	0 / 1102 (0.00%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
End stage renal disease			

subjects affected / exposed	1 / 1671 (0.06%)	1 / 1102 (0.09%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Hydronephrosis			
subjects affected / exposed	0 / 1671 (0.00%)	0 / 1102 (0.00%)	1 / 561 (0.18%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lupus nephritis			
subjects affected / exposed	2 / 1671 (0.12%)	1 / 1102 (0.09%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal failure			
subjects affected / exposed	1 / 1671 (0.06%)	1 / 1102 (0.09%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal infarct			
subjects affected / exposed	1 / 1671 (0.06%)	0 / 1102 (0.00%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal injury			
subjects affected / exposed	0 / 1671 (0.00%)	0 / 1102 (0.00%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal mass			
subjects affected / exposed	1 / 1671 (0.06%)	0 / 1102 (0.00%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Subcapsular renal haematoma			
subjects affected / exposed	1 / 1671 (0.06%)	0 / 1102 (0.00%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ureterolithiasis			

subjects affected / exposed	0 / 1671 (0.00%)	1 / 1102 (0.09%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary retention			
subjects affected / exposed	0 / 1671 (0.00%)	1 / 1102 (0.09%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Endocrine disorders			
Thyroid disorder			
subjects affected / exposed	0 / 1671 (0.00%)	0 / 1102 (0.00%)	1 / 561 (0.18%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
Back pain			
subjects affected / exposed	1 / 1671 (0.06%)	2 / 1102 (0.18%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Arthritis			
subjects affected / exposed	0 / 1671 (0.00%)	1 / 1102 (0.09%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Arthralgia			
subjects affected / exposed	0 / 1671 (0.00%)	1 / 1102 (0.09%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Chondrocalcinosis			
subjects affected / exposed	1 / 1671 (0.06%)	0 / 1102 (0.00%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Fracture nonunion			
subjects affected / exposed	1 / 1671 (0.06%)	0 / 1102 (0.00%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Immunoglobulin G4 related disease			
subjects affected / exposed	0 / 1671 (0.00%)	0 / 1102 (0.00%)	1 / 561 (0.18%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lumbar spinal stenosis			
subjects affected / exposed	1 / 1671 (0.06%)	1 / 1102 (0.09%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Joint destruction			
subjects affected / exposed	0 / 1671 (0.00%)	1 / 1102 (0.09%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intervertebral disc protrusion			
subjects affected / exposed	1 / 1671 (0.06%)	0 / 1102 (0.00%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Muscle spasms			
subjects affected / exposed	0 / 1671 (0.00%)	0 / 1102 (0.00%)	1 / 561 (0.18%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Osteoarthritis			
subjects affected / exposed	1 / 1671 (0.06%)	1 / 1102 (0.09%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal chest pain			
subjects affected / exposed	0 / 1671 (0.00%)	1 / 1102 (0.09%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Muscular weakness			
subjects affected / exposed	0 / 1671 (0.00%)	1 / 1102 (0.09%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Osteonecrosis			

subjects affected / exposed	0 / 1671 (0.00%)	1 / 1102 (0.09%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sacroiliitis			
subjects affected / exposed	1 / 1671 (0.06%)	0 / 1102 (0.00%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rheumatoid arthritis			
subjects affected / exposed	0 / 1671 (0.00%)	1 / 1102 (0.09%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 3	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rhabdomyolysis			
subjects affected / exposed	3 / 1671 (0.18%)	0 / 1102 (0.00%)	1 / 561 (0.18%)
occurrences causally related to treatment / all	0 / 3	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Psoriatic arthropathy			
subjects affected / exposed	1 / 1671 (0.06%)	0 / 1102 (0.00%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Systemic lupus erythematosus			
subjects affected / exposed	2 / 1671 (0.12%)	2 / 1102 (0.18%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Spinal stenosis			
subjects affected / exposed	0 / 1671 (0.00%)	1 / 1102 (0.09%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Spinal osteoarthritis			
subjects affected / exposed	0 / 1671 (0.00%)	0 / 1102 (0.00%)	1 / 561 (0.18%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Abscess limb			

subjects affected / exposed	1 / 1671 (0.06%)	2 / 1102 (0.18%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Abdominal abscess			
subjects affected / exposed	0 / 1671 (0.00%)	1 / 1102 (0.09%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Anal abscess			
subjects affected / exposed	1 / 1671 (0.06%)	0 / 1102 (0.00%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Arteriovenous graft site infection			
subjects affected / exposed	0 / 1671 (0.00%)	1 / 1102 (0.09%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Appendicitis			
subjects affected / exposed	1 / 1671 (0.06%)	2 / 1102 (0.18%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Appendicitis perforated			
subjects affected / exposed	2 / 1671 (0.12%)	0 / 1102 (0.00%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Arteriovenous fistula site infection			
subjects affected / exposed	0 / 1671 (0.00%)	1 / 1102 (0.09%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Atypical pneumonia			
subjects affected / exposed	1 / 1671 (0.06%)	0 / 1102 (0.00%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bacteraemia			

subjects affected / exposed	1 / 1671 (0.06%)	0 / 1102 (0.00%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Asymptomatic bacteriuria			
subjects affected / exposed	1 / 1671 (0.06%)	0 / 1102 (0.00%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Aspergillus infection			
subjects affected / exposed	0 / 1671 (0.00%)	1 / 1102 (0.09%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bacterial pyelonephritis			
subjects affected / exposed	2 / 1671 (0.12%)	0 / 1102 (0.00%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Arthritis bacterial			
subjects affected / exposed	1 / 1671 (0.06%)	0 / 1102 (0.00%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Arthritis infective			
subjects affected / exposed	0 / 1671 (0.00%)	0 / 1102 (0.00%)	1 / 561 (0.18%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bacterial sepsis			
subjects affected / exposed	0 / 1671 (0.00%)	0 / 1102 (0.00%)	1 / 561 (0.18%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bronchitis			
subjects affected / exposed	2 / 1671 (0.12%)	0 / 1102 (0.00%)	2 / 561 (0.36%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
COVID-19 pneumonia			

subjects affected / exposed	4 / 1671 (0.24%)	5 / 1102 (0.45%)	5 / 561 (0.89%)
occurrences causally related to treatment / all	0 / 4	0 / 5	0 / 5
deaths causally related to treatment / all	0 / 0	0 / 2	0 / 0
COVID-19			
subjects affected / exposed	15 / 1671 (0.90%)	10 / 1102 (0.91%)	1 / 561 (0.18%)
occurrences causally related to treatment / all	0 / 15	0 / 10	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bronchitis pneumococcal			
subjects affected / exposed	0 / 1671 (0.00%)	1 / 1102 (0.09%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bronchitis haemophilus			
subjects affected / exposed	0 / 1671 (0.00%)	1 / 1102 (0.09%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bronchitis bacterial			
subjects affected / exposed	1 / 1671 (0.06%)	1 / 1102 (0.09%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Campylobacter gastroenteritis			
subjects affected / exposed	1 / 1671 (0.06%)	0 / 1102 (0.00%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cellulitis enterococcal			
subjects affected / exposed	1 / 1671 (0.06%)	0 / 1102 (0.00%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cellulitis			
subjects affected / exposed	6 / 1671 (0.36%)	4 / 1102 (0.36%)	1 / 561 (0.18%)
occurrences causally related to treatment / all	0 / 6	0 / 4	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Catheter site cellulitis			

subjects affected / exposed	0 / 1671 (0.00%)	1 / 1102 (0.09%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac valve vegetation			
subjects affected / exposed	1 / 1671 (0.06%)	0 / 1102 (0.00%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Campylobacter infection			
subjects affected / exposed	1 / 1671 (0.06%)	0 / 1102 (0.00%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Central nervous system infection			
subjects affected / exposed	1 / 1671 (0.06%)	0 / 1102 (0.00%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Conjunctivitis			
subjects affected / exposed	0 / 1671 (0.00%)	1 / 1102 (0.09%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Colonic abscess			
subjects affected / exposed	1 / 1671 (0.06%)	1 / 1102 (0.09%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Clostridium difficile infection			
subjects affected / exposed	0 / 1671 (0.00%)	1 / 1102 (0.09%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Clostridium difficile colitis			
subjects affected / exposed	4 / 1671 (0.24%)	2 / 1102 (0.18%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 5	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Citrobacter bacteraemia			

subjects affected / exposed	0 / 1671 (0.00%)	1 / 1102 (0.09%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cystitis			
subjects affected / exposed	0 / 1671 (0.00%)	0 / 1102 (0.00%)	1 / 561 (0.18%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cystitis escherichia			
subjects affected / exposed	0 / 1671 (0.00%)	1 / 1102 (0.09%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cytomegalovirus infection			
subjects affected / exposed	0 / 1671 (0.00%)	1 / 1102 (0.09%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dengue fever			
subjects affected / exposed	0 / 1671 (0.00%)	1 / 1102 (0.09%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dengue haemorrhagic fever			
subjects affected / exposed	1 / 1671 (0.06%)	0 / 1102 (0.00%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Device related infection			
subjects affected / exposed	1 / 1671 (0.06%)	0 / 1102 (0.00%)	1 / 561 (0.18%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diarrhoea infectious			
subjects affected / exposed	1 / 1671 (0.06%)	0 / 1102 (0.00%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Disseminated cryptococcosis			

subjects affected / exposed	1 / 1671 (0.06%)	0 / 1102 (0.00%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Disseminated tuberculosis			
subjects affected / exposed	0 / 1671 (0.00%)	1 / 1102 (0.09%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diverticulitis			
subjects affected / exposed	1 / 1671 (0.06%)	4 / 1102 (0.36%)	2 / 561 (0.36%)
occurrences causally related to treatment / all	0 / 1	0 / 4	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diverticulitis intestinal perforated			
subjects affected / exposed	1 / 1671 (0.06%)	0 / 1102 (0.00%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Emphysematous cystitis			
subjects affected / exposed	0 / 1671 (0.00%)	1 / 1102 (0.09%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Emphysematous pyelonephritis			
subjects affected / exposed	0 / 1671 (0.00%)	1 / 1102 (0.09%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Empyema			
subjects affected / exposed	1 / 1671 (0.06%)	0 / 1102 (0.00%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Encephalomyelitis			
subjects affected / exposed	1 / 1671 (0.06%)	0 / 1102 (0.00%)	1 / 561 (0.18%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Endocarditis			

subjects affected / exposed	1 / 1671 (0.06%)	1 / 1102 (0.09%)	1 / 561 (0.18%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Enterococcal bacteraemia			
subjects affected / exposed	0 / 1671 (0.00%)	1 / 1102 (0.09%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Escherichia sepsis			
subjects affected / exposed	1 / 1671 (0.06%)	2 / 1102 (0.18%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Escherichia pyelonephritis			
subjects affected / exposed	1 / 1671 (0.06%)	1 / 1102 (0.09%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Escherichia bacteraemia			
subjects affected / exposed	1 / 1671 (0.06%)	1 / 1102 (0.09%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Erysipelas			
subjects affected / exposed	0 / 1671 (0.00%)	2 / 1102 (0.18%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Epstein-Barr virus infection			
subjects affected / exposed	1 / 1671 (0.06%)	0 / 1102 (0.00%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Epididymitis			
subjects affected / exposed	0 / 1671 (0.00%)	0 / 1102 (0.00%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Enterococcal sepsis			

subjects affected / exposed	0 / 1671 (0.00%)	1 / 1102 (0.09%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Groin abscess			
subjects affected / exposed	1 / 1671 (0.06%)	0 / 1102 (0.00%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis viral			
subjects affected / exposed	0 / 1671 (0.00%)	1 / 1102 (0.09%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis			
subjects affected / exposed	3 / 1671 (0.18%)	2 / 1102 (0.18%)	1 / 561 (0.18%)
occurrences causally related to treatment / all	0 / 3	1 / 2	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Fungal infection			
subjects affected / exposed	0 / 1671 (0.00%)	0 / 1102 (0.00%)	1 / 561 (0.18%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Escherichia urinary tract infection			
subjects affected / exposed	3 / 1671 (0.18%)	0 / 1102 (0.00%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 3	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatitis E			
subjects affected / exposed	0 / 1671 (0.00%)	0 / 1102 (0.00%)	1 / 561 (0.18%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Herpes zoster			
subjects affected / exposed	1 / 1671 (0.06%)	2 / 1102 (0.18%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Influenza			

subjects affected / exposed	6 / 1671 (0.36%)	3 / 1102 (0.27%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 6	0 / 3	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
JC virus infection			
subjects affected / exposed	0 / 1671 (0.00%)	0 / 1102 (0.00%)	1 / 561 (0.18%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Kidney infection			
subjects affected / exposed	0 / 1671 (0.00%)	0 / 1102 (0.00%)	1 / 561 (0.18%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Klebsiella bacteraemia			
subjects affected / exposed	0 / 1671 (0.00%)	1 / 1102 (0.09%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Histoplasmosis			
subjects affected / exposed	0 / 1671 (0.00%)	0 / 1102 (0.00%)	1 / 561 (0.18%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infection			
subjects affected / exposed	1 / 1671 (0.06%)	0 / 1102 (0.00%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infective exacerbation of chronic obstructive airways disease			
subjects affected / exposed	0 / 1671 (0.00%)	1 / 1102 (0.09%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Klebsiella sepsis			
subjects affected / exposed	0 / 1671 (0.00%)	0 / 1102 (0.00%)	1 / 561 (0.18%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Large intestine infection			

subjects affected / exposed	0 / 1671 (0.00%)	1 / 1102 (0.09%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Liver abscess			
subjects affected / exposed	0 / 1671 (0.00%)	1 / 1102 (0.09%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Medical device site joint infection			
subjects affected / exposed	1 / 1671 (0.06%)	0 / 1102 (0.00%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lower respiratory tract infection			
subjects affected / exposed	0 / 1671 (0.00%)	1 / 1102 (0.09%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Measles			
subjects affected / exposed	0 / 1671 (0.00%)	0 / 1102 (0.00%)	1 / 561 (0.18%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Localised infection			
subjects affected / exposed	1 / 1671 (0.06%)	0 / 1102 (0.00%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metapneumovirus pneumonia			
subjects affected / exposed	1 / 1671 (0.06%)	1 / 1102 (0.09%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Necrotising soft tissue infection			
subjects affected / exposed	0 / 1671 (0.00%)	0 / 1102 (0.00%)	1 / 561 (0.18%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Neutropenic sepsis			

subjects affected / exposed	0 / 1671 (0.00%)	4 / 1102 (0.36%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 4	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Norovirus infection			
subjects affected / exposed	0 / 1671 (0.00%)	1 / 1102 (0.09%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Oesophageal candidiasis			
subjects affected / exposed	1 / 1671 (0.06%)	0 / 1102 (0.00%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Osteomyelitis			
subjects affected / exposed	3 / 1671 (0.18%)	1 / 1102 (0.09%)	1 / 561 (0.18%)
occurrences causally related to treatment / all	0 / 3	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Otitis media			
subjects affected / exposed	0 / 1671 (0.00%)	1 / 1102 (0.09%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Parainfluenzae virus infection			
subjects affected / exposed	0 / 1671 (0.00%)	1 / 1102 (0.09%)	1 / 561 (0.18%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pelvic abscess			
subjects affected / exposed	0 / 1671 (0.00%)	0 / 1102 (0.00%)	1 / 561 (0.18%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Peritonitis			
subjects affected / exposed	3 / 1671 (0.18%)	1 / 1102 (0.09%)	1 / 561 (0.18%)
occurrences causally related to treatment / all	0 / 3	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Peritonitis bacterial			

subjects affected / exposed	1 / 1671 (0.06%)	0 / 1102 (0.00%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pilonidal disease			
subjects affected / exposed	1 / 1671 (0.06%)	0 / 1102 (0.00%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumococcal infection			
subjects affected / exposed	0 / 1671 (0.00%)	1 / 1102 (0.09%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumocystis jirovecii pneumonia			
subjects affected / exposed	1 / 1671 (0.06%)	1 / 1102 (0.09%)	1 / 561 (0.18%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia			
subjects affected / exposed	32 / 1671 (1.92%)	15 / 1102 (1.36%)	6 / 561 (1.07%)
occurrences causally related to treatment / all	0 / 34	0 / 15	0 / 6
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Pneumonia bacterial			
subjects affected / exposed	3 / 1671 (0.18%)	0 / 1102 (0.00%)	2 / 561 (0.36%)
occurrences causally related to treatment / all	0 / 3	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia haemophilus			
subjects affected / exposed	2 / 1671 (0.12%)	0 / 1102 (0.00%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia influenzal			
subjects affected / exposed	0 / 1671 (0.00%)	1 / 1102 (0.09%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia mycoplasmal			

subjects affected / exposed	2 / 1671 (0.12%)	0 / 1102 (0.00%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia necrotising			
subjects affected / exposed	1 / 1671 (0.06%)	0 / 1102 (0.00%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia pneumococcal			
subjects affected / exposed	1 / 1671 (0.06%)	1 / 1102 (0.09%)	1 / 561 (0.18%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia respiratory syncytial viral			
subjects affected / exposed	1 / 1671 (0.06%)	0 / 1102 (0.00%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary sepsis			
subjects affected / exposed	0 / 1671 (0.00%)	1 / 1102 (0.09%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Progressive multifocal leukoencephalopathy			
subjects affected / exposed	0 / 1671 (0.00%)	0 / 1102 (0.00%)	1 / 561 (0.18%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Postoperative wound infection			
subjects affected / exposed	0 / 1671 (0.00%)	1 / 1102 (0.09%)	1 / 561 (0.18%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Post procedural infection			
subjects affected / exposed	0 / 1671 (0.00%)	1 / 1102 (0.09%)	1 / 561 (0.18%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia viral			

subjects affected / exposed	1 / 1671 (0.06%)	2 / 1102 (0.18%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia staphylococcal			
subjects affected / exposed	1 / 1671 (0.06%)	0 / 1102 (0.00%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia serratia			
subjects affected / exposed	0 / 1671 (0.00%)	1 / 1102 (0.09%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal graft infection			
subjects affected / exposed	1 / 1671 (0.06%)	0 / 1102 (0.00%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyomyositis			
subjects affected / exposed	1 / 1671 (0.06%)	0 / 1102 (0.00%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyelonephritis acute			
subjects affected / exposed	2 / 1671 (0.12%)	1 / 1102 (0.09%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyelonephritis			
subjects affected / exposed	2 / 1671 (0.12%)	2 / 1102 (0.18%)	1 / 561 (0.18%)
occurrences causally related to treatment / all	0 / 2	0 / 2	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary tuberculosis			
subjects affected / exposed	0 / 1671 (0.00%)	1 / 1102 (0.09%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory syncytial virus bronchitis			

subjects affected / exposed	0 / 1671 (0.00%)	0 / 1102 (0.00%)	1 / 561 (0.18%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory syncytial virus infection			
subjects affected / exposed	1 / 1671 (0.06%)	0 / 1102 (0.00%)	1 / 561 (0.18%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Septic pulmonary embolism			
subjects affected / exposed	1 / 1671 (0.06%)	0 / 1102 (0.00%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sepsis			
subjects affected / exposed	12 / 1671 (0.72%)	9 / 1102 (0.82%)	4 / 561 (0.71%)
occurrences causally related to treatment / all	0 / 12	0 / 9	0 / 4
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Rickettsiosis			
subjects affected / exposed	0 / 1671 (0.00%)	1 / 1102 (0.09%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rhinovirus infection			
subjects affected / exposed	0 / 1671 (0.00%)	1 / 1102 (0.09%)	1 / 561 (0.18%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory tract infection viral			
subjects affected / exposed	1 / 1671 (0.06%)	0 / 1102 (0.00%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory tract infection bacterial			
subjects affected / exposed	1 / 1671 (0.06%)	0 / 1102 (0.00%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Septic shock			

subjects affected / exposed	14 / 1671 (0.84%)	4 / 1102 (0.36%)	3 / 561 (0.53%)
occurrences causally related to treatment / all	0 / 15	0 / 4	0 / 3
deaths causally related to treatment / all	0 / 5	0 / 2	0 / 1
Staphylococcal bacteraemia			
subjects affected / exposed	4 / 1671 (0.24%)	1 / 1102 (0.09%)	2 / 561 (0.36%)
occurrences causally related to treatment / all	0 / 4	0 / 1	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Staphylococcal infection			
subjects affected / exposed	0 / 1671 (0.00%)	2 / 1102 (0.18%)	1 / 561 (0.18%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Staphylococcal sepsis			
subjects affected / exposed	2 / 1671 (0.12%)	0 / 1102 (0.00%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Stenotrophomonas infection			
subjects affected / exposed	0 / 1671 (0.00%)	1 / 1102 (0.09%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Stenotrophomonas maltophilia pneumonia			
subjects affected / exposed	1 / 1671 (0.06%)	0 / 1102 (0.00%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Streptococcal infection			
subjects affected / exposed	0 / 1671 (0.00%)	0 / 1102 (0.00%)	1 / 561 (0.18%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Streptococcal sepsis			
subjects affected / exposed	2 / 1671 (0.12%)	0 / 1102 (0.00%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Urinary tract infection pseudomonal			

subjects affected / exposed	1 / 1671 (0.06%)	0 / 1102 (0.00%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary tract infection fungal			
subjects affected / exposed	1 / 1671 (0.06%)	0 / 1102 (0.00%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary tract infection bacterial			
subjects affected / exposed	0 / 1671 (0.00%)	2 / 1102 (0.18%)	1 / 561 (0.18%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary tract infection			
subjects affected / exposed	8 / 1671 (0.48%)	6 / 1102 (0.54%)	1 / 561 (0.18%)
occurrences causally related to treatment / all	0 / 9	0 / 6	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Upper respiratory tract infection			
subjects affected / exposed	0 / 1671 (0.00%)	1 / 1102 (0.09%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Superinfection bacterial			
subjects affected / exposed	0 / 1671 (0.00%)	0 / 1102 (0.00%)	1 / 561 (0.18%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urosepsis			
subjects affected / exposed	4 / 1671 (0.24%)	3 / 1102 (0.27%)	1 / 561 (0.18%)
occurrences causally related to treatment / all	0 / 4	0 / 3	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular access site cellulitis			
subjects affected / exposed	1 / 1671 (0.06%)	0 / 1102 (0.00%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Varicella			

subjects affected / exposed	1 / 1671 (0.06%)	0 / 1102 (0.00%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Viral sepsis			
subjects affected / exposed	0 / 1671 (0.00%)	2 / 1102 (0.18%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Wound cellulitis			
subjects affected / exposed	1 / 1671 (0.06%)	0 / 1102 (0.00%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Wound infection			
subjects affected / exposed	1 / 1671 (0.06%)	0 / 1102 (0.00%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Wound infection staphylococcal			
subjects affected / exposed	1 / 1671 (0.06%)	0 / 1102 (0.00%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders			
Decreased appetite			
subjects affected / exposed	0 / 1671 (0.00%)	1 / 1102 (0.09%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dehydration			
subjects affected / exposed	1 / 1671 (0.06%)	2 / 1102 (0.18%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diabetic ketoacidosis			
subjects affected / exposed	0 / 1671 (0.00%)	0 / 1102 (0.00%)	1 / 561 (0.18%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyperglycaemia			

subjects affected / exposed	0 / 1671 (0.00%)	2 / 1102 (0.18%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gout			
subjects affected / exposed	0 / 1671 (0.00%)	1 / 1102 (0.09%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Electrolyte imbalance			
subjects affected / exposed	1 / 1671 (0.06%)	0 / 1102 (0.00%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyperkalaemia			
subjects affected / exposed	8 / 1671 (0.48%)	8 / 1102 (0.73%)	1 / 561 (0.18%)
occurrences causally related to treatment / all	0 / 8	0 / 12	0 / 1
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Hypoglycaemia			
subjects affected / exposed	1 / 1671 (0.06%)	3 / 1102 (0.27%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 4	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypervolaemia			
subjects affected / exposed	11 / 1671 (0.66%)	10 / 1102 (0.91%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 13	0 / 14	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypernatraemia			
subjects affected / exposed	1 / 1671 (0.06%)	0 / 1102 (0.00%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypokalaemia			
subjects affected / exposed	0 / 1671 (0.00%)	0 / 1102 (0.00%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyponatraemia			

subjects affected / exposed	0 / 1671 (0.00%)	1 / 1102 (0.09%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypovolaemia			
subjects affected / exposed	1 / 1671 (0.06%)	0 / 1102 (0.00%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Type 2 diabetes mellitus			
subjects affected / exposed	1 / 1671 (0.06%)	1 / 1102 (0.09%)	0 / 561 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Serious adverse events	EVUSHELD 300 mg-Sub Study	AZD3152 1200 mg-Sub Study	AZD5156- Sentinel Cohort
Total subjects affected by serious adverse events			
subjects affected / exposed	11 / 158 (6.96%)	15 / 310 (4.84%)	2 / 41 (4.88%)
number of deaths (all causes)	0	2	1
number of deaths resulting from adverse events	0	2	1
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Acute myeloid leukaemia			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Acute myeloid leukaemia refractory			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Anaplastic large cell lymphoma T- and null-cell types			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Adenocarcinoma of colon			

subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Adenocarcinoma gastric			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
B-cell lymphoma			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
B-cell small lymphocytic lymphoma			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bladder cancer			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Brain neoplasm			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bronchial carcinoma			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Central nervous system lymphoma			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cholangiocarcinoma			

subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Chronic lymphocytic leukaemia			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Clear cell renal cell carcinoma			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Follicular lymphoma stage IV			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Follicular lymphoma			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Endometrial cancer metastatic			
subjects affected / exposed	0 / 158 (0.00%)	1 / 310 (0.32%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diffuse large B-cell lymphoma			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Colorectal cancer metastatic			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Colon cancer metastatic			

subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hormone receptor positive breast cancer			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intestinal adenocarcinoma			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Invasive ductal breast carcinoma			
subjects affected / exposed	1 / 158 (0.63%)	1 / 310 (0.32%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
High-grade B-cell lymphoma			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatocellular carcinoma			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Glioma			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lung adenocarcinoma			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Mantle cell lymphoma recurrent			

subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Malignant neoplasm progression			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Malignant melanoma in situ			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lymphoma			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Marginal zone lymphoma			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Myelodysplastic syndrome			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Non-Hodgkin's lymphoma			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Non-small cell lung cancer			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Non-small cell lung cancer metastatic			

subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Oesophageal adenocarcinoma			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ovarian cancer			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pancreatic carcinoma			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Papillary thyroid cancer			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Plasma cell myeloma			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rectal cancer stage IV			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Prostate cancer stage IV			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Prostate cancer metastatic			

subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Prostate cancer			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Post transplant lymphoproliferative disorder			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Plasma cell myeloma recurrent			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Squamous cell carcinoma of skin			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Squamous cell carcinoma			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Skin squamous cell carcinoma metastatic			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal neoplasm			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal cell carcinoma			

subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal cancer metastatic			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
T-cell lymphoma			
subjects affected / exposed	0 / 158 (0.00%)	1 / 310 (0.32%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Uterine leiomyoma			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Transitional cell carcinoma metastatic			
subjects affected / exposed	0 / 158 (0.00%)	1 / 310 (0.32%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Transitional cell carcinoma			
subjects affected / exposed	0 / 158 (0.00%)	1 / 310 (0.32%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Throat cancer			
subjects affected / exposed	1 / 158 (0.63%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular disorders			
Aortic dissection			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Aneurysm ruptured			

subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haematoma			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dialysis hypotension			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Deep vein thrombosis			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Brachiocephalic vein thrombosis			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Arterial thrombosis			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Aortitis			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Aortic stenosis			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Jugular vein thrombosis			

subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypovolaemic shock			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypotension			
subjects affected / exposed	1 / 158 (0.63%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypertensive urgency			
subjects affected / exposed	1 / 158 (0.63%)	1 / 310 (0.32%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypertensive emergency			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypertensive crisis			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypertension			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Orthostatic hypotension			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Peripheral arterial occlusive disease			

subjects affected / exposed	1 / 158 (0.63%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Peripheral ischaemia			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Peripheral venous disease			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Raynaud's phenomenon			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Shock haemorrhagic			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Superficial vein thrombosis			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Venous stenosis			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Surgical and medical procedures			
Toe amputation			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			

Adhesion			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Asthenia			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Chest pain			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Death			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gait disturbance			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Drug withdrawal syndrome			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General physical health deterioration			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injection site necrosis			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Multiple organ dysfunction syndrome			

subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Non-cardiac chest pain			
subjects affected / exposed	0 / 158 (0.00%)	1 / 310 (0.32%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyrexia			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Systemic inflammatory response syndrome			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Generalised oedema			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Immune system disorders			
Anaphylactic reaction			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Kidney transplant rejection			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infusion related hypersensitivity reaction			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypersensitivity			

subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Graft versus host disease			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Drug hypersensitivity			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cytokine release syndrome			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Anti-neutrophil cytoplasmic antibody positive vasculitis			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Transplant rejection			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Liver transplant rejection			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Reproductive system and breast disorders			
Cervical dysplasia			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cystocele			

subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Endometrial hyperplasia			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ovarian cyst			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pelvic pain			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Prostatitis			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Aspiration			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Acute respiratory failure			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Acute pulmonary oedema			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Asthma			

subjects affected / exposed	0 / 158 (0.00%)	1 / 310 (0.32%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Chronic obstructive pulmonary disease			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bronchiectasis			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bronchial hyperreactivity			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Interstitial lung disease			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypoxia			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haemothorax			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haemoptysis			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dyspnoea			

subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Chronic rhinosinusitis with nasal polyps			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pleural effusion			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumothorax			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary embolism			
subjects affected / exposed	0 / 158 (0.00%)	2 / 310 (0.65%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Organising pneumonia			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Malignant pleural effusion			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary fibrosis			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lupus pleurisy			

subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary hypertension			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory failure			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory arrest			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary oedema			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary infarction			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary haemorrhage			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Psychiatric disorders			
Alcohol withdrawal syndrome			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bipolar disorder			

subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Psychotic disorder			
subjects affected / exposed	1 / 158 (0.63%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Post-traumatic stress disorder			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Mental status changes			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Suicide attempt			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Product issues			
Device malfunction			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Investigations			
International normalised ratio increased			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Influenza A virus test positive			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Anticoagulation drug level above therapeutic			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Troponin increased			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
White blood cell count decreased			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
Accidental overdose			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Anaemia postoperative			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Acetabulum fracture			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Anastomotic ulcer			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Arteriovenous fistula thrombosis			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Arteriovenous fistula site complication			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Arteriovenous fistula occlusion			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ankle fracture			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Arteriovenous graft thrombosis			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Complications of transplanted kidney			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Comminuted fracture			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cervical vertebral fracture			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Burns second degree			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cystitis radiation			

subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Deep vein thrombosis postoperative			
subjects affected / exposed	0 / 158 (0.00%)	1 / 310 (0.32%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Fall			
subjects affected / exposed	1 / 158 (0.63%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Femoral neck fracture			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Femur fracture			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Fibula fracture			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Foot fracture			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal stoma complication			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Incisional hernia, obstructive			

subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyphaema			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Humerus fracture			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrostomy tube site complication			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Graft haemorrhage			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hip fracture			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intentional overdose			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Post procedural complication			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Post procedural bile leak			

subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pelvic fracture			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Multiple fractures			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lower limb fracture			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Limb injury			
subjects affected / exposed	0 / 158 (0.00%)	1 / 310 (0.32%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Post procedural fever			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Post procedural haemorrhage			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Postoperative respiratory failure			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Procedural haemorrhage			

subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Radius fracture			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal transplant failure			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rib fracture			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Spinal compression fracture			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Spinal fracture			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Spleen contusion			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Subcutaneous haematoma			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Subdural haemorrhage			

subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tendon injury			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tendon rupture			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Upper limb fracture			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ulna fracture			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tibia fracture			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular access site thrombosis			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Wound dehiscence			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular graft occlusion			

subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular graft complication			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Congenital, familial and genetic disorders			
Haemorrhagic arteriovenous malformation			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
Acute right ventricular failure			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Acute myocardial infarction			
subjects affected / exposed	0 / 158 (0.00%)	1 / 310 (0.32%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Acute left ventricular failure			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Acute coronary syndrome			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Angina pectoris			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Arteriosclerosis coronary artery			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Angina unstable			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Atrial fibrillation			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Atrial flutter			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Atrioventricular block complete			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Atrioventricular block second degree			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bradycardia			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac failure			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac arrest			

subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac failure acute			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardio-respiratory arrest			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac valve disease			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac failure congestive			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiogenic shock			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Coronary artery disease			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Heart failure with preserved ejection fraction			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Heart failure with reduced ejection fraction			

subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypertensive heart disease			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Left ventricular dysfunction			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Mitral valve incompetence			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Myocardial infarction			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pericardial effusion			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tachycardia			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Supraventricular tachycardia			
subjects affected / exposed	1 / 158 (0.63%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pericarditis			

subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ventricular extrasystoles			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ventricular fibrillation			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ventricular tachyarrhythmia			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ventricular tachycardia			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Brain stem haemorrhage			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Brain injury			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ataxia			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Aphasia			

subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Altered state of consciousness			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Central nervous system lupus			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cauda equina syndrome			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Carotid artery disease			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Carotid arteriosclerosis			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Brain stem stroke			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Brain stem infarction			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diabetic neuropathy			

subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cervical radiculopathy			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cerebrovascular accident			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cerebral microinfarction			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cerebral infarction			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cerebral haemorrhage			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Embolic stroke			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haemorrhagic stroke			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Headache			

subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Focal dyscognitive seizures			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Facial paralysis			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haemorrhage intracranial			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Encephalopathy			
subjects affected / exposed	1 / 158 (0.63%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Epilepsy			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Idiopathic intracranial hypertension			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intracranial aneurysm			
subjects affected / exposed	1 / 158 (0.63%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ischaemic stroke			

subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Migraine			
subjects affected / exposed	1 / 158 (0.63%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolic encephalopathy			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Multiple sclerosis relapse			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Myasthenia gravis			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Myasthenia gravis crisis			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Myelopathy			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nerve compression			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Neurotoxicity			

subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Partial seizures			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Multiple sclerosis			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Toxic encephalopathy			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tension headache			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Syncope			
subjects affected / exposed	1 / 158 (0.63%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Phrenic nerve paralysis			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sciatica			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Seizure			

subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
VIth nerve paralysis			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Trigeminal neuralgia			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Transient ischaemic attack			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood and lymphatic system disorders			
Agranulocytosis			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Anaemia			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Autoimmune neutropenia			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bicytopenia			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Febrile neutropenia			

subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood loss anaemia			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Immune-mediated pancytopenia			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Iron deficiency anaemia			
subjects affected / exposed	1 / 158 (0.63%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Neutropenia			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nephrogenic anaemia			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pancytopenia			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Splenic infarction			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Thrombocytopenia			

subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Eye disorders			
Glaucoma			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diabetic retinal oedema			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cataract			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Retinal vein occlusion			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Colitis			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ascites			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Abdominal wall cyst			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Abdominal pain upper			

subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Abdominal pain			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Abdominal hernia			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Abdominal adhesions			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Colitis ischaemic			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Duodenal ulcer haemorrhage			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Duodenal stenosis			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diverticulum intestinal haemorrhagic			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diverticulum intestinal			

subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diarrhoea			
subjects affected / exposed	0 / 158 (0.00%)	1 / 310 (0.32%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Colitis ulcerative			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastritis haemorrhagic			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastritis			
subjects affected / exposed	0 / 158 (0.00%)	1 / 310 (0.32%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Food poisoning			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Fistula of small intestine			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Femoral hernia			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal haemorrhage			

subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Faecaloma			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal polyp haemorrhage			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal pain			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haematemesis			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Inguinal hernia			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Impaired gastric emptying			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ileus			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hiatus hernia			

subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Large intestine perforation			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Large intestinal ulcer perforation			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intra-abdominal haemorrhage			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intestinal perforation			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intestinal obstruction			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Internal hernia			
subjects affected / exposed	0 / 158 (0.00%)	1 / 310 (0.32%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Oesophagitis			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Oesophageal stenosis			

subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Oedematous pancreatitis			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Obstructive pancreatitis			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nausea			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lower gastrointestinal haemorrhage			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Oral macule			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pancreatitis acute			
subjects affected / exposed	0 / 158 (0.00%)	2 / 310 (0.65%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pancreatitis necrotising			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Retroperitoneal haematoma			

subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Small intestinal obstruction			
subjects affected / exposed	0 / 158 (0.00%)	1 / 310 (0.32%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Stomatitis			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Umbilical hernia			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Upper gastrointestinal haemorrhage			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Volvulus of small bowel			
subjects affected / exposed	0 / 158 (0.00%)	1 / 310 (0.32%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vomiting			
subjects affected / exposed	1 / 158 (0.63%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatobiliary disorders			
Cholecystitis acute			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cholecystitis			

subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Biliary obstruction			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Autoimmune hepatitis			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Acute cholecystitis necrotic			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cholecystitis chronic			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cholelithiasis			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Drug-induced liver injury			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Jaundice cholestatic			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatitis toxic			

subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatitis acute			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatic cirrhosis			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Skin and subcutaneous tissue disorders			
Pruritus			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Erythema nodosum			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diabetic foot			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Skin mass			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			
Bladder perforation			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Azotaemia			

subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Acute kidney injury			
subjects affected / exposed	0 / 158 (0.00%)	1 / 310 (0.32%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Chronic kidney disease			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nephrolithiasis			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nephrotic syndrome			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal artery stenosis			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cystitis haemorrhagic			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
End stage renal disease			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hydronephrosis			

subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lupus nephritis			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal failure			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal infarct			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal injury			
subjects affected / exposed	0 / 158 (0.00%)	1 / 310 (0.32%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal mass			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Subcapsular renal haematoma			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ureterolithiasis			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary retention			

subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Endocrine disorders			
Thyroid disorder			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
Back pain			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Arthritis			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Arthralgia			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Chondrocalcinosis			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Fracture nonunion			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Immunoglobulin G4 related disease			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Lumbar spinal stenosis			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Joint destruction			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intervertebral disc protrusion			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Muscle spasms			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Osteoarthritis			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal chest pain			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Muscular weakness			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Osteonecrosis			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sacroiliitis			

subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rheumatoid arthritis			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rhabdomyolysis			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Psoriatic arthropathy			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Systemic lupus erythematosus			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Spinal stenosis			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Spinal osteoarthritis			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Abscess limb			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Abdominal abscess			

subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Anal abscess			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Arteriovenous graft site infection			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Appendicitis			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Appendicitis perforated			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Arteriovenous fistula site infection			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Atypical pneumonia			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bacteraemia			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Asymptomatic bacteriuria			

subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Aspergillus infection			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bacterial pyelonephritis			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Arthritis bacterial			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Arthritis infective			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bacterial sepsis			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bronchitis			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
COVID-19 pneumonia			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
COVID-19			

subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bronchitis pneumococcal			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bronchitis haemophilus			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bronchitis bacterial			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Campylobacter gastroenteritis			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cellulitis enterococcal			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cellulitis			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Catheter site cellulitis			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac valve vegetation			

subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Campylobacter infection			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Central nervous system infection			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Conjunctivitis			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Colonic abscess			
subjects affected / exposed	0 / 158 (0.00%)	1 / 310 (0.32%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Clostridium difficile infection			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Clostridium difficile colitis			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Citrobacter bacteraemia			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cystitis			

subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cystitis escherichia			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cytomegalovirus infection			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dengue fever			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dengue haemorrhagic fever			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Device related infection			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diarrhoea infectious			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Disseminated cryptococcosis			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Disseminated tuberculosis			

subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diverticulitis			
subjects affected / exposed	0 / 158 (0.00%)	1 / 310 (0.32%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diverticulitis intestinal perforated			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Emphysematous cystitis			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Emphysematous pyelonephritis			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Empyema			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Encephalomyelitis			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Endocarditis			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Enterococcal bacteraemia			

subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Escherichia sepsis			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Escherichia pyelonephritis			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Escherichia bacteraemia			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Erysipelas			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Epstein-Barr virus infection			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Epididymitis			
subjects affected / exposed	0 / 158 (0.00%)	1 / 310 (0.32%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Enterococcal sepsis			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Groin abscess			

subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis viral			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	1 / 41 (2.44%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Fungal infection			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Escherichia urinary tract infection			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatitis E			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Herpes zoster			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Influenza			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
JC virus infection			

subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Kidney infection			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Klebsiella bacteraemia			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Histoplasmosis			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infection			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infective exacerbation of chronic obstructive airways disease			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Klebsiella sepsis			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Large intestine infection			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Liver abscess			

subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Medical device site joint infection			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lower respiratory tract infection			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Measles			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Localised infection			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metapneumovirus pneumonia			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Necrotising soft tissue infection			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Neutropenic sepsis			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Norovirus infection			

subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Oesophageal candidiasis			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Osteomyelitis			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Otitis media			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Parainfluenzae virus infection			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pelvic abscess			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Peritonitis			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Peritonitis bacterial			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pilonidal disease			

subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumococcal infection			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumocystis jirovecii pneumonia			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia			
subjects affected / exposed	1 / 158 (0.63%)	1 / 310 (0.32%)	1 / 41 (2.44%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Pneumonia bacterial			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia haemophilus			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia influenzal			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia mycoplasmal			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia necrotising			

subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia pneumococcal			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia respiratory syncytial viral			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary sepsis			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Progressive multifocal leukoencephalopathy			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Postoperative wound infection			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Post procedural infection			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia viral			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia staphylococcal			

subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia serratia			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal graft infection			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyomyositis			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyelonephritis acute			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyelonephritis			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary tuberculosis			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory syncytial virus bronchitis			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory syncytial virus infection			

subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Septic pulmonary embolism			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sepsis			
subjects affected / exposed	0 / 158 (0.00%)	1 / 310 (0.32%)	1 / 41 (2.44%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rickettsiosis			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rhinovirus infection			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory tract infection viral			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory tract infection bacterial			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Septic shock			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Staphylococcal bacteraemia			

subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Staphylococcal infection			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Staphylococcal sepsis			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Stenotrophomonas infection			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Stenotrophomonas maltophilia pneumonia			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Streptococcal infection			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Streptococcal sepsis			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary tract infection pseudomonal			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary tract infection fungal			

subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary tract infection bacterial			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary tract infection			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Upper respiratory tract infection			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Superinfection bacterial			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urosepsis			
subjects affected / exposed	0 / 158 (0.00%)	1 / 310 (0.32%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular access site cellulitis			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Varicella			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Viral sepsis			

subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Wound cellulitis			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Wound infection			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Wound infection staphylococcal			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders			
Decreased appetite			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dehydration			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diabetic ketoacidosis			
subjects affected / exposed	1 / 158 (0.63%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyperglycaemia			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gout			

subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Electrolyte imbalance			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyperkalaemia			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypoglycaemia			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypervolaemia			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypernatraemia			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypokalaemia			
subjects affected / exposed	1 / 158 (0.63%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyponatraemia			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	1 / 41 (2.44%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypovolaemia			

subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Type 2 diabetes mellitus			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Serious adverse events	Placebo- Sentinel Cohort		
Total subjects affected by serious adverse events			
subjects affected / exposed	0 / 16 (0.00%)		
number of deaths (all causes)	0		
number of deaths resulting from adverse events	0		
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Acute myeloid leukaemia			
subjects affected / exposed	0 / 16 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Acute myeloid leukaemia refractory			
subjects affected / exposed	0 / 16 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Anaplastic large cell lymphoma T- and null-cell types			
subjects affected / exposed	0 / 16 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Adenocarcinoma of colon			
subjects affected / exposed	0 / 16 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Adenocarcinoma gastric			

subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
B-cell lymphoma				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
B-cell small lymphocytic lymphoma				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Bladder cancer				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Brain neoplasm				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Bronchial carcinoma				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Central nervous system lymphoma				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Cholangiocarcinoma				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Chronic lymphocytic leukaemia				

subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Clear cell renal cell carcinoma				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Follicular lymphoma stage IV				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Follicular lymphoma				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Endometrial cancer metastatic				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Diffuse large B-cell lymphoma				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Colorectal cancer metastatic				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Colon cancer metastatic				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Hormone receptor positive breast cancer				

subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Intestinal adenocarcinoma				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Invasive ductal breast carcinoma				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
High-grade B-cell lymphoma				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Hepatocellular carcinoma				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Glioma				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Lung adenocarcinoma				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Mantle cell lymphoma recurrent				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Malignant neoplasm progression				

subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Malignant melanoma in situ				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Lymphoma				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Marginal zone lymphoma				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Myelodysplastic syndrome				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Non-Hodgkin's lymphoma				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Non-small cell lung cancer				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Non-small cell lung cancer metastatic				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Oesophageal adenocarcinoma				

subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Ovarian cancer				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Pancreatic carcinoma				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Papillary thyroid cancer				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Plasma cell myeloma				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Rectal cancer stage IV				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Prostate cancer stage IV				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Prostate cancer metastatic				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Prostate cancer				

subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Post transplant lymphoproliferative disorder				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Plasma cell myeloma recurrent				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Squamous cell carcinoma of skin				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Squamous cell carcinoma				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Skin squamous cell carcinoma metastatic				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Renal neoplasm				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Renal cell carcinoma				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Renal cancer metastatic				

subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
T-cell lymphoma				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Uterine leiomyoma				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Transitional cell carcinoma metastatic				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Transitional cell carcinoma				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Throat cancer				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Vascular disorders				
Aortic dissection				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Aneurysm ruptured				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Haematoma				

subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Dialysis hypotension				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Deep vein thrombosis				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Brachiocephalic vein thrombosis				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Arterial thrombosis				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Aortitis				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Aortic stenosis				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Jugular vein thrombosis				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Hypovolaemic shock				

subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Hypotension				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Hypertensive urgency				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Hypertensive emergency				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Hypertensive crisis				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Hypertension				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Orthostatic hypotension				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Peripheral arterial occlusive disease				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Peripheral ischaemia				

subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Peripheral venous disease				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Raynaud's phenomenon				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Shock haemorrhagic				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Superficial vein thrombosis				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Venous stenosis				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Surgical and medical procedures				
Toe amputation				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
General disorders and administration site conditions				
Adhesion				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			

Asthenia				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Chest pain				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Death				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Gait disturbance				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Drug withdrawal syndrome				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
General physical health deterioration				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Injection site necrosis				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Multiple organ dysfunction syndrome				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Non-cardiac chest pain				

subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Pyrexia				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Systemic inflammatory response syndrome				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Generalised oedema				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Immune system disorders				
Anaphylactic reaction				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Kidney transplant rejection				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Infusion related hypersensitivity reaction				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Hypersensitivity				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Graft versus host disease				

subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Drug hypersensitivity				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Cytokine release syndrome				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Anti-neutrophil cytoplasmic antibody positive vasculitis				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Transplant rejection				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Liver transplant rejection				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Reproductive system and breast disorders				
Cervical dysplasia				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Cystocele				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Endometrial hyperplasia				

subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Ovarian cyst				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Pelvic pain				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Prostatitis				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Respiratory, thoracic and mediastinal disorders				
Aspiration				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Acute respiratory failure				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Acute pulmonary oedema				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Asthma				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Chronic obstructive pulmonary disease				

subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Bronchiectasis				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Bronchial hyperreactivity				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Interstitial lung disease				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Hypoxia				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Haemothorax				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Haemoptysis				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Dyspnoea				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Chronic rhinosinusitis with nasal polyps				

subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Pleural effusion				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Pneumothorax				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Pulmonary embolism				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Organising pneumonia				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Malignant pleural effusion				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Pulmonary fibrosis				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Lupus pleurisy				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Pulmonary hypertension				

subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Respiratory failure				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Respiratory arrest				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Pulmonary oedema				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Pulmonary infarction				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Pulmonary haemorrhage				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Psychiatric disorders				
Alcohol withdrawal syndrome				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Bipolar disorder				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Psychotic disorder				

subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Post-traumatic stress disorder				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Mental status changes				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Suicide attempt				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Product issues				
Device malfunction				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Investigations				
International normalised ratio increased				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Influenza A virus test positive				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Anticoagulation drug level above therapeutic				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			

Troponin increased				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
White blood cell count decreased				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Injury, poisoning and procedural complications				
Accidental overdose				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Anaemia postoperative				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Acetabulum fracture				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Anastomotic ulcer				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Arteriovenous fistula thrombosis				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Arteriovenous fistula site complication				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			

Arteriovenous fistula occlusion				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Ankle fracture				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Arteriovenous graft thrombosis				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Complications of transplanted kidney				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Comminuted fracture				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Cervical vertebral fracture				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Burns second degree				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Cystitis radiation				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Deep vein thrombosis postoperative				

subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Fall				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Femoral neck fracture				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Femur fracture				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Fibula fracture				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Foot fracture				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Gastrointestinal stoma complication				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Incisional hernia, obstructive				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Hyphaema				

subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Humerus fracture				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Gastrostomy tube site complication				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Graft haemorrhage				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Hip fracture				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Intentional overdose				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Post procedural complication				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Post procedural bile leak				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Pelvic fracture				

subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Multiple fractures				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Lower limb fracture				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Limb injury				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Post procedural fever				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Post procedural haemorrhage				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Postoperative respiratory failure				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Procedural haemorrhage				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Radius fracture				

subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Renal transplant failure				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Rib fracture				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Spinal compression fracture				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Spinal fracture				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Spleen contusion				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Subcutaneous haematoma				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Subdural haemorrhage				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Tendon injury				

subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Tendon rupture				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Upper limb fracture				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Ulna fracture				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Tibia fracture				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Vascular access site thrombosis				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Wound dehiscence				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Vascular graft occlusion				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Vascular graft complication				

subjects affected / exposed	0 / 16 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Congenital, familial and genetic disorders			
Haemorrhagic arteriovenous malformation			
subjects affected / exposed	0 / 16 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Cardiac disorders			
Acute right ventricular failure			
subjects affected / exposed	0 / 16 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Acute myocardial infarction			
subjects affected / exposed	0 / 16 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Acute left ventricular failure			
subjects affected / exposed	0 / 16 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Acute coronary syndrome			
subjects affected / exposed	0 / 16 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Angina pectoris			
subjects affected / exposed	0 / 16 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Arteriosclerosis coronary artery			
subjects affected / exposed	0 / 16 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		

Angina unstable				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Atrial fibrillation				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Atrial flutter				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Atrioventricular block complete				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Atrioventricular block second degree				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Bradycardia				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Cardiac failure				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Cardiac arrest				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Cardiac failure acute				

subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Cardio-respiratory arrest				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Cardiac valve disease				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Cardiac failure congestive				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Cardiogenic shock				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Coronary artery disease				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Heart failure with preserved ejection fraction				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Heart failure with reduced ejection fraction				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Hypertensive heart disease				

subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Left ventricular dysfunction				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Mitral valve incompetence				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Myocardial infarction				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Pericardial effusion				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Tachycardia				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Supraventricular tachycardia				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Pericarditis				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Ventricular extrasystoles				

subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Ventricular fibrillation				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Ventricular tachyarrhythmia				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Ventricular tachycardia				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Nervous system disorders				
Brain stem haemorrhage				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Brain injury				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Ataxia				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Aphasia				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Altered state of consciousness				

subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Central nervous system lupus				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Cauda equina syndrome				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Carotid artery disease				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Carotid arteriosclerosis				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Brain stem stroke				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Brain stem infarction				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Diabetic neuropathy				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Cervical radiculopathy				

subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Cerebrovascular accident				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Cerebral microinfarction				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Cerebral infarction				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Cerebral haemorrhage				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Embolic stroke				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Haemorrhagic stroke				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Headache				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Focal dyscognitive seizures				

subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Facial paralysis				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Haemorrhage intracranial				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Encephalopathy				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Epilepsy				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Idiopathic intracranial hypertension				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Intracranial aneurysm				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Ischaemic stroke				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Migraine				

subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Metabolic encephalopathy				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Multiple sclerosis relapse				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Myasthenia gravis				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Myasthenia gravis crisis				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Myelopathy				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Nerve compression				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Neurotoxicity				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Partial seizures				

subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Multiple sclerosis				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Toxic encephalopathy				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Tension headache				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Syncope				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Phrenic nerve paralysis				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Sciatica				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Seizure				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
VIth nerve paralysis				

subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Trigeminal neuralgia				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Transient ischaemic attack				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Blood and lymphatic system disorders				
Agranulocytosis				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Anaemia				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Autoimmune neutropenia				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Bicytopenia				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Febrile neutropenia				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Blood loss anaemia				

subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Immune-mediated pancytopenia				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Iron deficiency anaemia				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Neutropenia				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Nephrogenic anaemia				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Pancytopenia				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Splenic infarction				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Thrombocytopenia				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Eye disorders				
Glaucoma				

subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Diabetic retinal oedema				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Cataract				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Retinal vein occlusion				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Gastrointestinal disorders				
Colitis				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Ascites				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Abdominal wall cyst				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Abdominal pain upper				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Abdominal pain				

subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Abdominal hernia				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Abdominal adhesions				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Colitis ischaemic				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Duodenal ulcer haemorrhage				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Duodenal stenosis				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Diverticulum intestinal haemorrhagic				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Diverticulum intestinal				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Diarrhoea				

subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Colitis ulcerative				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Gastritis haemorrhagic				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Gastritis				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Food poisoning				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Fistula of small intestine				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Femoral hernia				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Gastrointestinal haemorrhage				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Faecaloma				

subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Gastrointestinal polyp haemorrhage				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Gastrointestinal pain				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Haematemesis				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Inguinal hernia				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Impaired gastric emptying				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Ileus				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Hiatus hernia				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Large intestine perforation				

subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Large intestinal ulcer perforation				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Intra-abdominal haemorrhage				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Intestinal perforation				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Intestinal obstruction				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Internal hernia				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Oesophagitis				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Oesophageal stenosis				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Oedematous pancreatitis				

subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Obstructive pancreatitis				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Nausea				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Lower gastrointestinal haemorrhage				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Oral macule				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Pancreatitis acute				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Pancreatitis necrotising				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Retroperitoneal haematoma				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Small intestinal obstruction				

subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Stomatitis				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Umbilical hernia				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Upper gastrointestinal haemorrhage				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Volvulus of small bowel				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Vomiting				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Hepatobiliary disorders				
Cholecystitis acute				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Cholecystitis				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Biliary obstruction				

subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Autoimmune hepatitis				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Acute cholecystitis necrotic				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Cholecystitis chronic				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Cholelithiasis				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Drug-induced liver injury				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Jaundice cholestatic				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Hepatitis toxic				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Hepatitis acute				

subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Hepatic cirrhosis				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Skin and subcutaneous tissue disorders				
Pruritus				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Erythema nodosum				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Diabetic foot				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Skin mass				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Renal and urinary disorders				
Bladder perforation				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Azotaemia				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Acute kidney injury				

subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Chronic kidney disease				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Nephrolithiasis				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Nephrotic syndrome				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Renal artery stenosis				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Cystitis haemorrhagic				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
End stage renal disease				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Hydronephrosis				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Lupus nephritis				

subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Renal failure				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Renal infarct				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Renal injury				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Renal mass				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Subcapsular renal haematoma				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Ureterolithiasis				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Urinary retention				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Endocrine disorders				
Thyroid disorder				

subjects affected / exposed	0 / 16 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Musculoskeletal and connective tissue disorders			
Back pain			
subjects affected / exposed	0 / 16 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Arthritis			
subjects affected / exposed	0 / 16 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Arthralgia			
subjects affected / exposed	0 / 16 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Chondrocalcinosis			
subjects affected / exposed	0 / 16 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Fracture nonunion			
subjects affected / exposed	0 / 16 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Immunoglobulin G4 related disease			
subjects affected / exposed	0 / 16 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Lumbar spinal stenosis			
subjects affected / exposed	0 / 16 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Joint destruction			

subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Intervertebral disc protrusion				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Muscle spasms				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Osteoarthritis				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Musculoskeletal chest pain				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Muscular weakness				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Osteonecrosis				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Sacroiliitis				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Rheumatoid arthritis				

subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Rhabdomyolysis				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Psoriatic arthropathy				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Systemic lupus erythematosus				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Spinal stenosis				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Spinal osteoarthritis				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Infections and infestations				
Abscess limb				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Abdominal abscess				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Anal abscess				

subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Arteriovenous graft site infection				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Appendicitis				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Appendicitis perforated				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Arteriovenous fistula site infection				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Atypical pneumonia				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Bacteraemia				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Asymptomatic bacteriuria				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Aspergillus infection				

subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Bacterial pyelonephritis				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Arthritis bacterial				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Arthritis infective				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Bacterial sepsis				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Bronchitis				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
COVID-19 pneumonia				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
COVID-19				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Bronchitis pneumococcal				

subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Bronchitis haemophilus				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Bronchitis bacterial				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Campylobacter gastroenteritis				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Cellulitis enterococcal				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Cellulitis				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Catheter site cellulitis				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Cardiac valve vegetation				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Campylobacter infection				

subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Central nervous system infection				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Conjunctivitis				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Colonic abscess				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Clostridium difficile infection				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Clostridium difficile colitis				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Citrobacter bacteraemia				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Cystitis				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Cystitis escherichia				

subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Cytomegalovirus infection				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Dengue fever				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Dengue haemorrhagic fever				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Device related infection				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Diarrhoea infectious				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Disseminated cryptococcosis				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Disseminated tuberculosis				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Diverticulitis				

subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Diverticulitis intestinal perforated				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Emphysematous cystitis				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Emphysematous pyelonephritis				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Empyema				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Encephalomyelitis				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Endocarditis				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Enterococcal bacteraemia				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Escherichia sepsis				

subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Escherichia pyelonephritis				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Escherichia bacteraemia				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Erysipelas				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Epstein-Barr virus infection				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Epididymitis				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Enterococcal sepsis				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Groin abscess				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Gastroenteritis viral				

subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Gastroenteritis				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Fungal infection				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Escherichia urinary tract infection				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Hepatitis E				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Herpes zoster				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Influenza				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
JC virus infection				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Kidney infection				

subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Klebsiella bacteraemia				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Histoplasmosis				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Infection				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Infective exacerbation of chronic obstructive airways disease				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Klebsiella sepsis				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Large intestine infection				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Liver abscess				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Medical device site joint infection				

subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Lower respiratory tract infection				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Measles				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Localised infection				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Metapneumovirus pneumonia				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Necrotising soft tissue infection				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Neutropenic sepsis				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Norovirus infection				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Oesophageal candidiasis				

subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Osteomyelitis				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Otitis media				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Parainfluenzae virus infection				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Pelvic abscess				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Peritonitis				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Peritonitis bacterial				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Pilonidal disease				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Pneumococcal infection				

subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Pneumocystis jirovecii pneumonia				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Pneumonia				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Pneumonia bacterial				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Pneumonia haemophilus				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Pneumonia influenzal				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Pneumonia mycoplasmal				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Pneumonia necrotising				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Pneumonia pneumococcal				

subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Pneumonia respiratory syncytial viral				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Pulmonary sepsis				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Progressive multifocal leukoencephalopathy				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Postoperative wound infection				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Post procedural infection				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Pneumonia viral				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Pneumonia staphylococcal				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Pneumonia serratia				

subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Renal graft infection				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Pyomyositis				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Pyelonephritis acute				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Pyelonephritis				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Pulmonary tuberculosis				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Respiratory syncytial virus bronchitis				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Respiratory syncytial virus infection				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Septic pulmonary embolism				

subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Sepsis				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Rickettsiosis				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Rhinovirus infection				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Respiratory tract infection viral				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Respiratory tract infection bacterial				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Septic shock				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Staphylococcal bacteraemia				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Staphylococcal infection				

subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Staphylococcal sepsis				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Stenotrophomonas infection				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Stenotrophomonas maltophilia pneumonia				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Streptococcal infection				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Streptococcal sepsis				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Urinary tract infection pseudomonal				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Urinary tract infection fungal				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Urinary tract infection bacterial				

subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Urinary tract infection				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Upper respiratory tract infection				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Superinfection bacterial				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Urosepsis				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Vascular access site cellulitis				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Varicella				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Viral sepsis				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Wound cellulitis				

subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Wound infection				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Wound infection staphylococcal				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Metabolism and nutrition disorders				
Decreased appetite				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Dehydration				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Diabetic ketoacidosis				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Hyperglycaemia				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Gout				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Electrolyte imbalance				

subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Hyperkalaemia				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Hypoglycaemia				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Hypervolaemia				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Hypernatraemia				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Hypokalaemia				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Hyponatraemia				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Hypovolaemia				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Type 2 diabetes mellitus				

subjects affected / exposed	0 / 16 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		

Frequency threshold for reporting non-serious adverse events: 2 %

Non-serious adverse events	AZD3152- Main Cohort	AZD7442- Main Cohort	Placebo- Main Cohort
Total subjects affected by non-serious adverse events			
subjects affected / exposed	892 / 1671 (53.38%)	627 / 1102 (56.90%)	295 / 561 (52.58%)
Vascular disorders			
Hypertension			
subjects affected / exposed	51 / 1671 (3.05%)	40 / 1102 (3.63%)	21 / 561 (3.74%)
occurrences (all)	54	41	22
General disorders and administration site conditions			
Asthenia			
subjects affected / exposed	39 / 1671 (2.33%)	26 / 1102 (2.36%)	8 / 561 (1.43%)
occurrences (all)	40	29	8
Injection site pain			
subjects affected / exposed	33 / 1671 (1.97%)	29 / 1102 (2.63%)	7 / 561 (1.25%)
occurrences (all)	34	33	8
Injection site pruritus			
subjects affected / exposed	3 / 1671 (0.18%)	2 / 1102 (0.18%)	0 / 561 (0.00%)
occurrences (all)	3	2	0
Non-cardiac chest pain			
subjects affected / exposed	4 / 1671 (0.24%)	4 / 1102 (0.36%)	2 / 561 (0.36%)
occurrences (all)	4	4	2
Peripheral swelling			
subjects affected / exposed	4 / 1671 (0.24%)	2 / 1102 (0.18%)	2 / 561 (0.36%)
occurrences (all)	4	2	2
Pyrexia			
subjects affected / exposed	53 / 1671 (3.17%)	43 / 1102 (3.90%)	15 / 561 (2.67%)
occurrences (all)	62	45	20
Fatigue			
subjects affected / exposed	98 / 1671 (5.86%)	69 / 1102 (6.26%)	35 / 561 (6.24%)
occurrences (all)	109	77	39

Reproductive system and breast disorders			
Dysmenorrhoea			
subjects affected / exposed	0 / 1671 (0.00%)	0 / 1102 (0.00%)	0 / 561 (0.00%)
occurrences (all)	0	0	0
Respiratory, thoracic and mediastinal disorders			
Wheezing			
subjects affected / exposed	1 / 1671 (0.06%)	0 / 1102 (0.00%)	1 / 561 (0.18%)
occurrences (all)	1	0	1
Rhinorrhoea			
subjects affected / exposed	70 / 1671 (4.19%)	59 / 1102 (5.35%)	18 / 561 (3.21%)
occurrences (all)	85	68	20
Oropharyngeal pain			
subjects affected / exposed	96 / 1671 (5.75%)	58 / 1102 (5.26%)	22 / 561 (3.92%)
occurrences (all)	119	70	24
Nasal congestion			
subjects affected / exposed	58 / 1671 (3.47%)	27 / 1102 (2.45%)	13 / 561 (2.32%)
occurrences (all)	62	33	13
Cough			
subjects affected / exposed	144 / 1671 (8.62%)	111 / 1102 (10.07%)	25 / 561 (4.46%)
occurrences (all)	170	135	33
Investigations			
SARS-CoV-2 test positive			
subjects affected / exposed	29 / 1671 (1.74%)	23 / 1102 (2.09%)	3 / 561 (0.53%)
occurrences (all)	29	23	3
Injury, poisoning and procedural complications			
Fall			
subjects affected / exposed	39 / 1671 (2.33%)	25 / 1102 (2.27%)	14 / 561 (2.50%)
occurrences (all)	41	26	14
Contusion			
subjects affected / exposed	10 / 1671 (0.60%)	11 / 1102 (1.00%)	7 / 561 (1.25%)
occurrences (all)	11	13	9
Nervous system disorders			
Dizziness			
subjects affected / exposed	17 / 1671 (1.02%)	19 / 1102 (1.72%)	9 / 561 (1.60%)
occurrences (all)	21	21	9
Syncope			

subjects affected / exposed	8 / 1671 (0.48%)	3 / 1102 (0.27%)	2 / 561 (0.36%)
occurrences (all)	9	3	2
Migraine			
subjects affected / exposed	5 / 1671 (0.30%)	5 / 1102 (0.45%)	5 / 561 (0.89%)
occurrences (all)	5	6	5
Headache			
subjects affected / exposed	128 / 1671 (7.66%)	83 / 1102 (7.53%)	36 / 561 (6.42%)
occurrences (all)	154	97	46
Ear and labyrinth disorders			
Motion sickness			
subjects affected / exposed	0 / 1671 (0.00%)	0 / 1102 (0.00%)	0 / 561 (0.00%)
occurrences (all)	0	0	0
Gastrointestinal disorders			
Abdominal pain			
subjects affected / exposed	22 / 1671 (1.32%)	8 / 1102 (0.73%)	6 / 561 (1.07%)
occurrences (all)	22	11	10
Food poisoning			
subjects affected / exposed	4 / 1671 (0.24%)	0 / 1102 (0.00%)	3 / 561 (0.53%)
occurrences (all)	4	0	3
Diarrhoea			
subjects affected / exposed	72 / 1671 (4.31%)	53 / 1102 (4.81%)	23 / 561 (4.10%)
occurrences (all)	78	65	27
Abdominal pain lower			
subjects affected / exposed	5 / 1671 (0.30%)	0 / 1102 (0.00%)	1 / 561 (0.18%)
occurrences (all)	5	0	1
Gastrooesophageal reflux disease			
subjects affected / exposed	14 / 1671 (0.84%)	10 / 1102 (0.91%)	4 / 561 (0.71%)
occurrences (all)	14	11	4
Nausea			
subjects affected / exposed	54 / 1671 (3.23%)	34 / 1102 (3.09%)	17 / 561 (3.03%)
occurrences (all)	57	35	19
Oral pain			
subjects affected / exposed	0 / 1671 (0.00%)	2 / 1102 (0.18%)	0 / 561 (0.00%)
occurrences (all)	0	2	0
Vomiting			

subjects affected / exposed	34 / 1671 (2.03%)	17 / 1102 (1.54%)	11 / 561 (1.96%)
occurrences (all)	38	17	11
Skin and subcutaneous tissue disorders			
Dermatitis			
subjects affected / exposed	1 / 1671 (0.06%)	1 / 1102 (0.09%)	1 / 561 (0.18%)
occurrences (all)	1	1	1
Acne			
subjects affected / exposed	1 / 1671 (0.06%)	1 / 1102 (0.09%)	0 / 561 (0.00%)
occurrences (all)	1	1	0
Dermatitis atopic			
subjects affected / exposed	5 / 1671 (0.30%)	1 / 1102 (0.09%)	0 / 561 (0.00%)
occurrences (all)	5	1	0
Ingrowing nail			
subjects affected / exposed	0 / 1671 (0.00%)	2 / 1102 (0.18%)	1 / 561 (0.18%)
occurrences (all)	0	2	1
Renal and urinary disorders			
Haematuria			
subjects affected / exposed	3 / 1671 (0.18%)	1 / 1102 (0.09%)	2 / 561 (0.36%)
occurrences (all)	4	1	2
Musculoskeletal and connective tissue disorders			
Back pain			
subjects affected / exposed	20 / 1671 (1.20%)	25 / 1102 (2.27%)	18 / 561 (3.21%)
occurrences (all)	20	25	20
Arthralgia			
subjects affected / exposed	34 / 1671 (2.03%)	22 / 1102 (2.00%)	9 / 561 (1.60%)
occurrences (all)	39	24	10
Myalgia			
subjects affected / exposed	37 / 1671 (2.21%)	32 / 1102 (2.90%)	17 / 561 (3.03%)
occurrences (all)	39	36	19
Rheumatoid arthritis			
subjects affected / exposed	24 / 1671 (1.44%)	25 / 1102 (2.27%)	12 / 561 (2.14%)
occurrences (all)	35	33	17
Infections and infestations			
Nasopharyngitis			
subjects affected / exposed	77 / 1671 (4.61%)	41 / 1102 (3.72%)	24 / 561 (4.28%)
occurrences (all)	85	45	27

Influenza			
subjects affected / exposed	37 / 1671 (2.21%)	14 / 1102 (1.27%)	8 / 561 (1.43%)
occurrences (all)	38	14	8
Gastroenteritis viral			
subjects affected / exposed	3 / 1671 (0.18%)	2 / 1102 (0.18%)	2 / 561 (0.36%)
occurrences (all)	3	2	2
Gastritis viral			
subjects affected / exposed	0 / 1671 (0.00%)	0 / 1102 (0.00%)	0 / 561 (0.00%)
occurrences (all)	0	0	0
Conjunctivitis			
subjects affected / exposed	17 / 1671 (1.02%)	12 / 1102 (1.09%)	3 / 561 (0.53%)
occurrences (all)	17	12	3
COVID-19			
subjects affected / exposed	273 / 1671 (16.34%)	205 / 1102 (18.60%)	112 / 561 (19.96%)
occurrences (all)	293	218	116
Bronchitis			
subjects affected / exposed	49 / 1671 (2.93%)	30 / 1102 (2.72%)	7 / 561 (1.25%)
occurrences (all)	56	33	8
Respiratory tract infection viral			
subjects affected / exposed	2 / 1671 (0.12%)	0 / 1102 (0.00%)	1 / 561 (0.18%)
occurrences (all)	2	0	1
Rhinitis			
subjects affected / exposed	41 / 1671 (2.45%)	27 / 1102 (2.45%)	10 / 561 (1.78%)
occurrences (all)	47	32	11
Viral upper respiratory tract infection			
subjects affected / exposed	19 / 1671 (1.14%)	11 / 1102 (1.00%)	9 / 561 (1.60%)
occurrences (all)	25	15	10
Urinary tract infection			
subjects affected / exposed	87 / 1671 (5.21%)	60 / 1102 (5.44%)	27 / 561 (4.81%)
occurrences (all)	125	85	31
Sinusitis			
subjects affected / exposed	50 / 1671 (2.99%)	34 / 1102 (3.09%)	18 / 561 (3.21%)
occurrences (all)	62	42	21
Upper respiratory tract infection			

subjects affected / exposed	121 / 1671 (7.24%)	63 / 1102 (5.72%)	44 / 561 (7.84%)
occurrences (all)	150	69	50
Ureaplasma infection			
subjects affected / exposed	0 / 1671 (0.00%)	0 / 1102 (0.00%)	0 / 561 (0.00%)
occurrences (all)	0	0	0

Non-serious adverse events	EVUSHELD 300 mg-Sub Study	AZD3152 1200 mg-Sub Study	AZD5156- Sentinel Cohort
Total subjects affected by non-serious adverse events			
subjects affected / exposed	18 / 158 (11.39%)	39 / 310 (12.58%)	19 / 41 (46.34%)
Vascular disorders			
Hypertension			
subjects affected / exposed	2 / 158 (1.27%)	5 / 310 (1.61%)	0 / 41 (0.00%)
occurrences (all)	2	5	0
General disorders and administration site conditions			
Asthenia			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences (all)	0	0	0
Injection site pain			
subjects affected / exposed	1 / 158 (0.63%)	0 / 310 (0.00%)	2 / 41 (4.88%)
occurrences (all)	1	0	2
Injection site pruritus			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	1 / 41 (2.44%)
occurrences (all)	0	0	1
Non-cardiac chest pain			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	1 / 41 (2.44%)
occurrences (all)	0	0	1
Peripheral swelling			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	1 / 41 (2.44%)
occurrences (all)	0	0	1
Pyrexia			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences (all)	0	0	0
Fatigue			
subjects affected / exposed	2 / 158 (1.27%)	4 / 310 (1.29%)	0 / 41 (0.00%)
occurrences (all)	2	4	0
Reproductive system and breast disorders			

Dysmenorrhoea			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	1 / 41 (2.44%)
occurrences (all)	0	0	1
Respiratory, thoracic and mediastinal disorders			
Wheezing			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	1 / 41 (2.44%)
occurrences (all)	0	0	1
Rhinorrhoea			
subjects affected / exposed	1 / 158 (0.63%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences (all)	1	0	0
Oropharyngeal pain			
subjects affected / exposed	2 / 158 (1.27%)	0 / 310 (0.00%)	2 / 41 (4.88%)
occurrences (all)	2	0	2
Nasal congestion			
subjects affected / exposed	1 / 158 (0.63%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences (all)	1	0	0
Cough			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	1 / 41 (2.44%)
occurrences (all)	0	0	1
Investigations			
SARS-CoV-2 test positive			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences (all)	0	0	0
Injury, poisoning and procedural complications			
Fall			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences (all)	0	0	0
Contusion			
subjects affected / exposed	0 / 158 (0.00%)	1 / 310 (0.32%)	1 / 41 (2.44%)
occurrences (all)	0	1	1
Nervous system disorders			
Dizziness			
subjects affected / exposed	0 / 158 (0.00%)	2 / 310 (0.65%)	1 / 41 (2.44%)
occurrences (all)	0	2	1
Syncope			

subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	1 / 41 (2.44%)
occurrences (all)	0	0	1
Migraine			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	1 / 41 (2.44%)
occurrences (all)	0	0	1
Headache			
subjects affected / exposed	2 / 158 (1.27%)	5 / 310 (1.61%)	4 / 41 (9.76%)
occurrences (all)	2	5	4
Ear and labyrinth disorders			
Motion sickness			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences (all)	0	0	0
Gastrointestinal disorders			
Abdominal pain			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences (all)	0	0	0
Food poisoning			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	1 / 41 (2.44%)
occurrences (all)	0	0	1
Diarrhoea			
subjects affected / exposed	1 / 158 (0.63%)	7 / 310 (2.26%)	0 / 41 (0.00%)
occurrences (all)	1	7	0
Abdominal pain lower			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	1 / 41 (2.44%)
occurrences (all)	0	0	1
Gastrooesophageal reflux disease			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	2 / 41 (4.88%)
occurrences (all)	0	0	2
Nausea			
subjects affected / exposed	1 / 158 (0.63%)	3 / 310 (0.97%)	1 / 41 (2.44%)
occurrences (all)	1	3	1
Oral pain			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	1 / 41 (2.44%)
occurrences (all)	0	0	1
Vomiting			

subjects affected / exposed	1 / 158 (0.63%)	1 / 310 (0.32%)	0 / 41 (0.00%)
occurrences (all)	1	1	0
Skin and subcutaneous tissue disorders			
Dermatitis			
subjects affected / exposed	0 / 158 (0.00%)	3 / 310 (0.97%)	1 / 41 (2.44%)
occurrences (all)	0	3	1
Acne			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	1 / 41 (2.44%)
occurrences (all)	0	0	1
Dermatitis atopic			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	1 / 41 (2.44%)
occurrences (all)	0	0	1
Ingrowing nail			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	1 / 41 (2.44%)
occurrences (all)	0	0	1
Renal and urinary disorders			
Haematuria			
subjects affected / exposed	0 / 158 (0.00%)	1 / 310 (0.32%)	0 / 41 (0.00%)
occurrences (all)	0	1	0
Musculoskeletal and connective tissue disorders			
Back pain			
subjects affected / exposed	0 / 158 (0.00%)	1 / 310 (0.32%)	0 / 41 (0.00%)
occurrences (all)	0	1	0
Arthralgia			
subjects affected / exposed	1 / 158 (0.63%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences (all)	1	0	0
Myalgia			
subjects affected / exposed	0 / 158 (0.00%)	2 / 310 (0.65%)	1 / 41 (2.44%)
occurrences (all)	0	3	1
Rheumatoid arthritis			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences (all)	0	0	0
Infections and infestations			
Nasopharyngitis			
subjects affected / exposed	1 / 158 (0.63%)	1 / 310 (0.32%)	0 / 41 (0.00%)
occurrences (all)	1	1	0

Influenza			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences (all)	0	0	0
Gastroenteritis viral			
subjects affected / exposed	0 / 158 (0.00%)	1 / 310 (0.32%)	1 / 41 (2.44%)
occurrences (all)	0	1	1
Gastritis viral			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences (all)	0	0	0
Conjunctivitis			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	1 / 41 (2.44%)
occurrences (all)	0	0	1
COVID-19			
subjects affected / exposed	4 / 158 (2.53%)	3 / 310 (0.97%)	1 / 41 (2.44%)
occurrences (all)	4	3	1
Bronchitis			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences (all)	0	0	0
Respiratory tract infection viral			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences (all)	0	0	0
Rhinitis			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	0 / 41 (0.00%)
occurrences (all)	0	0	0
Viral upper respiratory tract infection			
subjects affected / exposed	1 / 158 (0.63%)	0 / 310 (0.00%)	1 / 41 (2.44%)
occurrences (all)	1	0	1
Urinary tract infection			
subjects affected / exposed	1 / 158 (0.63%)	3 / 310 (0.97%)	1 / 41 (2.44%)
occurrences (all)	1	3	1
Sinusitis			
subjects affected / exposed	1 / 158 (0.63%)	1 / 310 (0.32%)	1 / 41 (2.44%)
occurrences (all)	1	1	1
Upper respiratory tract infection			
subjects affected / exposed	0 / 158 (0.00%)	3 / 310 (0.97%)	5 / 41 (12.20%)
occurrences (all)	0	3	7

Ureaplasma infection			
subjects affected / exposed	0 / 158 (0.00%)	0 / 310 (0.00%)	1 / 41 (2.44%)
occurrences (all)	0	0	1

Non-serious adverse events	Placebo- Sentinel Cohort		
Total subjects affected by non-serious adverse events			
subjects affected / exposed	12 / 16 (75.00%)		
Vascular disorders			
Hypertension			
subjects affected / exposed	0 / 16 (0.00%)		
occurrences (all)	0		
General disorders and administration site conditions			
Asthenia			
subjects affected / exposed	1 / 16 (6.25%)		
occurrences (all)	1		
Injection site pain			
subjects affected / exposed	2 / 16 (12.50%)		
occurrences (all)	3		
Injection site pruritus			
subjects affected / exposed	0 / 16 (0.00%)		
occurrences (all)	0		
Non-cardiac chest pain			
subjects affected / exposed	0 / 16 (0.00%)		
occurrences (all)	0		
Peripheral swelling			
subjects affected / exposed	0 / 16 (0.00%)		
occurrences (all)	0		
Pyrexia			
subjects affected / exposed	0 / 16 (0.00%)		
occurrences (all)	0		
Fatigue			
subjects affected / exposed	1 / 16 (6.25%)		
occurrences (all)	1		
Reproductive system and breast disorders			
Dysmenorrhoea			

subjects affected / exposed	0 / 16 (0.00%)		
occurrences (all)	0		
Respiratory, thoracic and mediastinal disorders			
Wheezing			
subjects affected / exposed	0 / 16 (0.00%)		
occurrences (all)	0		
Rhinorrhoea			
subjects affected / exposed	0 / 16 (0.00%)		
occurrences (all)	0		
Oropharyngeal pain			
subjects affected / exposed	1 / 16 (6.25%)		
occurrences (all)	1		
Nasal congestion			
subjects affected / exposed	1 / 16 (6.25%)		
occurrences (all)	1		
Cough			
subjects affected / exposed	1 / 16 (6.25%)		
occurrences (all)	1		
Investigations			
SARS-CoV-2 test positive			
subjects affected / exposed	0 / 16 (0.00%)		
occurrences (all)	0		
Injury, poisoning and procedural complications			
Fall			
subjects affected / exposed	0 / 16 (0.00%)		
occurrences (all)	0		
Contusion			
subjects affected / exposed	0 / 16 (0.00%)		
occurrences (all)	0		
Nervous system disorders			
Dizziness			
subjects affected / exposed	0 / 16 (0.00%)		
occurrences (all)	0		
Syncope			
subjects affected / exposed	0 / 16 (0.00%)		
occurrences (all)	0		

Migraine subjects affected / exposed occurrences (all)	0 / 16 (0.00%) 0		
Headache subjects affected / exposed occurrences (all)	3 / 16 (18.75%) 4		
Ear and labyrinth disorders Motion sickness subjects affected / exposed occurrences (all)	1 / 16 (6.25%) 1		
Gastrointestinal disorders Abdominal pain subjects affected / exposed occurrences (all)	1 / 16 (6.25%) 1		
Food poisoning subjects affected / exposed occurrences (all)	0 / 16 (0.00%) 0		
Diarrhoea subjects affected / exposed occurrences (all)	1 / 16 (6.25%) 2		
Abdominal pain lower subjects affected / exposed occurrences (all)	0 / 16 (0.00%) 0		
Gastrooesophageal reflux disease subjects affected / exposed occurrences (all)	0 / 16 (0.00%) 0		
Nausea subjects affected / exposed occurrences (all)	0 / 16 (0.00%) 0		
Oral pain subjects affected / exposed occurrences (all)	0 / 16 (0.00%) 0		
Vomiting subjects affected / exposed occurrences (all)	0 / 16 (0.00%) 0		
Skin and subcutaneous tissue disorders			

Dermatitis			
subjects affected / exposed	0 / 16 (0.00%)		
occurrences (all)	0		
Acne			
subjects affected / exposed	1 / 16 (6.25%)		
occurrences (all)	1		
Dermatitis atopic			
subjects affected / exposed	0 / 16 (0.00%)		
occurrences (all)	0		
Ingrowing nail			
subjects affected / exposed	0 / 16 (0.00%)		
occurrences (all)	0		
Renal and urinary disorders			
Haematuria			
subjects affected / exposed	1 / 16 (6.25%)		
occurrences (all)	1		
Musculoskeletal and connective tissue disorders			
Back pain			
subjects affected / exposed	0 / 16 (0.00%)		
occurrences (all)	0		
Arthralgia			
subjects affected / exposed	0 / 16 (0.00%)		
occurrences (all)	0		
Myalgia			
subjects affected / exposed	0 / 16 (0.00%)		
occurrences (all)	0		
Rheumatoid arthritis			
subjects affected / exposed	0 / 16 (0.00%)		
occurrences (all)	0		
Infections and infestations			
Nasopharyngitis			
subjects affected / exposed	0 / 16 (0.00%)		
occurrences (all)	0		
Influenza			
subjects affected / exposed	0 / 16 (0.00%)		
occurrences (all)	0		

Gastroenteritis viral				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences (all)	0			
Gastritis viral				
subjects affected / exposed	1 / 16 (6.25%)			
occurrences (all)	1			
Conjunctivitis				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences (all)	0			
COVID-19				
subjects affected / exposed	1 / 16 (6.25%)			
occurrences (all)	1			
Bronchitis				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences (all)	0			
Respiratory tract infection viral				
subjects affected / exposed	1 / 16 (6.25%)			
occurrences (all)	1			
Rhinitis				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences (all)	0			
Viral upper respiratory tract infection				
subjects affected / exposed	3 / 16 (18.75%)			
occurrences (all)	5			
Urinary tract infection				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences (all)	0			
Sinusitis				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences (all)	0			
Upper respiratory tract infection				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences (all)	0			
Ureaplasma infection				
subjects affected / exposed	0 / 16 (0.00%)			
occurrences (all)	0			

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
07 February 2023	The agent under study was changed from the mAb combination (AZD5156) to only one of its component mAbs (AZD3152) due to variant evolution. (v5)
24 May 2023	The sub-study was added as addendum and efficacy was upgraded to primary endpoint. (v6)
14 June 2023	The comparator was changed from Evusheld to placebo. (v7)
21 December 2023	A 2nd (dual) primary endpoint added to the trial. (v8)

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported